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Ovarian cancer, the most lethal of all gynecological malignancies, represents a significant public 
health burden to women worldwide.  The current challenges associated with ovarian cancer stem 
from a lack of effective screening strategies, an inability to detect the disease at a treatable stage, 
and the disappointing impact of treatment regimens over the entire disease course.  A multi-
faceted evaluation of circulating biomarkers of ovarian cancer was conducted in order to identify 
specific biomarkers and combinations which might serve as effective tools in the screening, 
triage, and therapeutic targeting of ovarian cancer patients.   
 Ovarian epithelial carcinoma (OEC) represents a heterogeneous disease characterized by 
several histological subtypes displaying divergent etiology, pathology, and treatment 
responsiveness.  Serum biomarkers were identified which displayed subtype-specific alterations 
in a comparison of OEC patients and benign controls.  These results suggest that circulating 
biomarkers may assist in the selection of patients for targeted therapies.   
 The efficient triage of women diagnosed with a pelvic mass based on risk of malignancy 
is known to result in a significant improvement in outcome for ovarian cancer patients and also a 
significant reduction in morbidity and anxiety for women with benign masses.  Several 
multimarker panels, including the optimal combination of CA 125 and HE4, were capable of 
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discriminating benign from malignant pelvic masses.  Based on current and previous findings, 
this biomarker panel may represent a novel diagnostic tool in this clinical setting.  
Urine may offer several distinct advantages over serum as an analytical biofluid based on 
its low complexity, high stability, and lack of invasivity.  An analysis of urine biomarkers 
revealed that several previously identified ovarian cancer biomarkers offer higher diagnostic 
performance in urine versus serum.  Urine multimarker panels were effective in discriminating 
ovarian cancer cases from controls while a combination of urine and serum biomarkers resulted 
in the highest performance.  
 The current study provides compelling evidence for the use of circulating biomarkers in 
several capacities within the setting of ovarian cancer.  The collective impact of biomarker 
research on the clinical management of ovarian cancer has the potential to significantly improve 
overall public health.        
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1.0  INTRODUCTION 
1.1 OVARIAN CANCER: EPIDEMIOLOGY AND ETIOLOGY 
Ovarian cancer represents the eighth most common cancer among women and the second most 
frequently diagnosed gynecological malignancy in the United States and Europe 1.  The overall 
global mortality attributed to ovarian cancer exceeds that of any other gynecological cancer with 
over 50% of the more than 200,000 women newly diagnosed each year expected to perish from 
the disease 2-5. A critical factor in the elevated mortality associated with ovarian cancer is the 
lack of disease-specific symptoms.  A high-profile consortium of public health organizations 
including the American Cancer Society, the Gynecological Cancer Foundation, and the Society 
of Gynecologic Oncologists recently issued a joint recommendation, termed the Ovarian Cancer 
Symptom Index (OCSI), which listed bloating, pelvic or abdominal pain, difficulty 
eating/fullness, and urinary symptoms as those more likely to occur in ovarian cancer patients 
than healthy women 6.  Compounding the problem of ubiquitous clinical presentation is the 
observation that the majority of early-stage cancers are asymptomatic resulting in over three-
quarters of all diagnoses being made at a time when the disease has already established regional 
or distant metastases 2. Despite aggressive cytoreductive surgery and platinum-based 
chemotherapy, the 5-year survival rate for patients with clinically advanced ovarian cancer is 
only 15-20%, although the cure rate for stage I disease is usually greater than 90% 2-4. Thus, 
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improved screening methodologies aimed at detecting ovarian cancer at its earliest stages have 
the potential to result in substantial improvements in overall survival for this disease.   
The lifetime risk of developing ovarian cancer stands at 1.39%, however this risk 
increases dramatically in women over the age of 45 (median age at diagnosis of 63) and in 
women with familial/hereditary conditions 5, 7.  In addition to age and genetic background, other 
risk factors associated with ovarian cancer include chronic inflammatory conditions/NSAID use, 
diet, ethnicity, hormone replacement therapy, hysterectomy, infertility drug use, obesity, OCP 
use, pregnancy, smoking, and exposure to talc or asbestos (reviewed in 8).  Hereditary ovarian 
cancer generally occurs within one of two distinct genetic backgrounds.  The first, hereditary 
breast and ovarian cancer (HBOC) syndrome, is attributable to germline mutations in the BRCA1 
or BRCA2 tumor suppressor genes 9-10, while the second is associated with hereditary non-
polyposis colorectal cancer (HNPCC), or Lynch Syndrome, which is attributable to a germline 
mutation in one of several genes located within the DNA mismatch repair pathway 11-12.  Recent 
evidence supports the notion that the genetic background underlying ovarian tumorigenesis 
extends well beyond these familial conditions and that the development of fully malignant 
tumors involves the progressive acquisition of mutations in multiple genes, including BRAF, 
KRAS, PTEN, Her2/neu, c-myc, p16, and p53 (reviewed in 13-15). Although these molecular 
alterations have been identified in a significant fraction of ovarian cancers, none of these 
mutations are diagnostic of malignancy or predictive of tumor behavior over time.  Furthermore, 
the frequency of several of the above mutations appears to be highly dependent on the 
histological subtype of the tumor 13.       
The precise etiology of ovarian cancer remains poorly characterized.  Factors including 
the rarity of the disease, its high rate of mortality, and the lack of useful experimental model 
 3 
systems have contributed to the challenging landscape facing ovarian cancer researchers.  A 
such, considerable controversy remains regarding the specific tissue origins and tumorigenic 
pathways involved.  Although several types of ovarian tumors of non-epithelial origin occur at 
low frequency 16, it is widely held that the vast majority of ovarian cancers, termed epithelial 
ovarian cancer (EOC), arise from the coelomic epithelium of the ovary.   Increasing evidence 
suggests that many of these tumors progress through a series of premalignant phases before 
becoming invasive 17-19 however, a premalignant lesion for ovarian cancer has yet to be 
identified. Invasive EOC can be further subdivided into the histological subtypes of serous, 
mucinous, endometrioid, clear cell and several other less common types.  Among these, serous is 
by far the most prevalent representing 75-80% of all EOCs 2.  Morphological similarities 
between each of these subtypes and tissues of the lower genital tract have led to the proposal of 
an alternative hypothesis suggesting that ovarian tumors could arise directly from these tissues of 
Mullerian embryological origin 20.  In either case it remains plausible that the various subtypes of 
epithelial ovarian cancer may represent divergent etiologies given the distinct patterns of 
differentiation and clinical characteristics they exhibit 21-22.  Several models of ovarian 
carcinogenesis have been proposed which describe a multifactorial process involving 
environmental, genetic, and endocrine components.  Popular among these models is the theory of 
incessant ovulation, which suggests that the repeated rupture/wounding of the ovarian surface 
followed by the rapid proliferation of surface epithelial cells that occurs during ovulation may 
facilitate malignant transformation of these cells 23.  Excessive gonadotropin and androgen 
stimulation of the ovary has also been postulated as a contributing factor 24.  A third theory 
proposes that EOC might arise as a result of exposure to toxic contaminants and carcinogens 
such as talc 25.  While each of these theories is supported by significant clinical evidence, none of 
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them are currently sufficient to describe a comprehensive mechanistic basis of ovarian cancer.  
Improved insights into the factors contributing to ovarian tumorigenesis, achieved through the 
utilization of novel methodologies, are therefore required to reconcile these models and further 
define disease etiology.      
1.2 OVARIAN CANCER SCREENING: CURRENT TRENDS AND OBSTACLES  
1.2.1 Screening Strategies  
The high mortality associated with epithelial ovarian cancer can be partially attributed to the lack 
of effective early detection methods.  Screening strategies capable of achieving the goal of early 
detection have the potential to dramatically enhance overall survival 4. A substantial amount of 
research is now focused on the development of improved methods of evaluating women at high 
risk of developing ovarian cancer. The information garnered from such research will provide a 
better understanding of the early events associated with the neoplastic process in the ovary, which 
remains disappointingly uncharacterized.  Although experimental evidence suggests the existence 
of a series of ovarian premalignant lesions demonstrating a cumulative array of molecular 
alterations, the definitive clinical identification of such lesions remains elusive.  Currently, 
women designated as high-risk for ovarian cancer must rely on genetic counseling and testing, 
which typically includes the measurement of serum CA 125 and transvaginal sonography (TVS) 
26.  The tumor marker CA 125 has demonstrated utility in monitoring the treatment response and 
progression of the disease, but not as a diagnostic or prognostic marker. Overall, the CA 125 
assay exhibits a sensitivity of only 50-60% for stage I disease, and has been shown to be 
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significantly less sensitive in premenopausal women in comparison to postmenopausal women 27-
29.  In light of these limitations, current recommendations do not favor the use of CA 125 for 
general screening.  Screening based on TVS, doppler and morphological indices has provided 
some encouraging results, however each of these methods currently lack the specificity required 
of a screening test for the general population 30.  A multimodal screening approach that combines 
the use of tumor markers measured at specific intervals with ultrasound may yield higher 
sensitivity and specificity.  An approach of this type has been evaluated in ovarian cancer and 
may represent a cost-effective strategy for early detection 31-32.  However, the current version of 
this strategy relies solely on CA 125 as the biomarker component and is therefore unlikely to 
provide sufficient sensitivity for early stage disease.  Thus, there is a critical need to develop 
additional informative biomarkers in order to achieve the requisite diagnostic performance 
necessary for clinical advancement.   
The requirements for a screening strategy for early stage ovarian cancer to be effective in 
the general population are considerable, and the feasibility of such an endeavor is the focus to two 
large, ongoing prospective randomized control trials (RCT): the Prostate, Lung, Colorectal, and 
Ovarian screening trial (PLCO, NCT00002540) sponsored by the National Cancer Institute, and 
the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS, 
NCT00058032) 33-34.  In a recent detailed meta-analysis, it was estimated that to achieve 50% 
sensitivity in detecting tumors before they advance to stage III, an annual screen would need to 
detect tumors 1.3 cm in diameter while an improvement to 80% sensitivity would require the 
detection of tumors less than 0.4 cm in diameter.  In addition, a 50% reduction in serous ovarian 
cancer mortality though annual screening would require a test capable of detecting tumors 0.5 cm 
in diameter 35. Considering the low prevalence of ovarian cancer in general population, any 
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proposed screening strategy must demonstrate a minimum specificity of 99.6% and a sensitivity 
of >75% for early stage disease to achieve a positive predictive value of 10% and avoid an 
unacceptable level of false-positive results 31-32.  Previous CA 125-based studies indicate that to 
meet these requirements, a first-line biomarker-based screening test would need to achieve a 
specificity of 98% 31-32.  As we await the results of the ongoing RCTs, a practical approach to 
ovarian cancer screening is the incorporation of serum biomarker testing into the evaluation of 
specific high-risk groups and clinical settings.  The enrichment of ovarian cancer cases within 
these settings may permit the achievement of promising results in the short-term.  With that goal 
in mind, the most pressing need to be addressed is the identification of novel biomarkers, or 
combinations of biomarkers that can detect small pre-symptomatic ovarian tumors and 
differentiate malignant from benign tumors with high levels of sensitivity and specificity.   
1.2.2 Biomarkers of Ovarian Cancer  
A number of cell-surface antigens and serum proteins are produced by ovarian tumors and can be 
assayed using monoclonal antibodies. Some of these assays have been applied clinically as 
markers of disease status and are useful in the detection of subclinical disease and in the 
diagnosis of recurrent ovarian cancer 36-37. As mentioned above, of all the serum biomarkers of 
ovarian cancer, CA 125 has been the most extensively studied, however a growing number of 
additional biomarkers elevated in patients with ovarian cancer have been identified (Table 1.1) 
including: CA 15-3, CA 54/61, CA 19-9, TAG-72, OVX1, M-CSF, carcinoembriogenic antigen 
(CEA), cancer-associated serum antigen (CASA), lipid-associated sialic acid (LASA), urinary 
gonadotropin fragment (UGF), HER2/neu (ErbB2), EGFR, sICAM-1, VEGF, and 
lysophosphatidic acid  28, 38-46.  In addition, several members of the kallikrein family of proteins 
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have been identified as potential serum markers of ovarian cancer 47-53.  The use of gene 
expression array analysis has identified a number of novel markers, including HE4 54, prostasin 
55  and osteopontin 56.  HE4, or human epididymus protein 4, is a secreted glycoprotein product 
of the WFDC2 gene which has shown great promise a diagnostic biomarker for ovarian cancer 
and has also recently been approved by the United States Food and Drug Administration for 
disease monitoring 57.  With the exception of HE4, the identification of additional biomarkers 
associated with ovarian cancer has not translated into widespread clinical implementation.  
Although several of these biomarkers are currently utilized clinically in other disease settings, 
most notably CA 15-3 and CA 19-9 for disease monitoring in breast and pancreatic cancer, 
respectively, none have shown significant diagnostic capabilities.   
 
Table 1.1  Previously described biomarkers associations in ovarian cancer 
Biomarker Description Method Reference 
CA 15-3 tumor antigen serum ELISA Woolas et al. 45 
CA 19-9 tumor antigen serum ELISA Woolas et al. 45 
TAG 72 tumor antigen serum ELISA Woolas et al.45 
CA 54/61 tumor antigen IHC Suzuki et al.41 
OVX1 tumor antigen serum RIA Woolas et al. 28 
M-CSF growth factor serum RIA Woolas et al.28 
CEA tumor antigen Luminex® (serum) Yurkovetsky et al.46 
CASA tumor antigen serum ELISA Sehouli et al.44 
LASA tumor antigen serum ELISA Crump et al. 43 
UGF tumor antigen serum ELISA Crump et al. 43 
HER2/neu growth factor receptor serum ELISA Crump et al. 43 
EGFR growth factor receptor MS/serum ELISA Baron et al.38 
sI-CAM1 adhesion molecule serum ELISA Callet et al.39 
VEGF angiogenesis factor serum ELISA Oehler et al.40 
Lysophosphaditic Acid mitogenic factor plasma ELISA Xu et al.42 
Kallikreins 4-8,11,15 proteases various methods Diamandis and colleagues47-53 
HE4 tumor antigen microarray Schummer et al.54 
Prostasin protease microarray Mok et al.55 
Osteopontin bone factor microarray Kim et al.56 
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The limited diagnostic performance demonstrated by each of the established and 
emerging biomarkers of ovarian cancer has led many investigators to focus on the use of 
multimarker panels in hopes of achieving superior sensitivity and specificity.  In preclinical 
testing, multimarker combinations containing CA 125 have generally demonstrated increases in 
sensitivity of 5-10% over CA 125 alone while maintaining a similar level of specificity.  The 
addition of known tumor markers such as CA 15-3, TAG 72 (CA 72-4), mesothelin, and OVX1 
to CA 125 has yielded promising results29, 58-61.  Among the highest performing models is a panel 
consisting of CA 125, leptin, prolactin, IGF-II, MIF, and osteopontin which demonstrated a 
sensitivity of 95.3% at a specificity of 99.4% 62.  This report illustrates a growing trend involving 
the incorporation of proteins unlikely to be derived from the tumor itself into discriminatory 
panels.  Several other examples of this include the addition of proteins such as M-CSF29, sIL-
2R63, sFas64, ApoA165, and transthyretin65 to CA 125 to achieve improved performance.  The 
various biomarkers utilized above represent factors originating from not only the growing tumor 
itself, but also from the stromal microenvironment surrounding the tumor and elements of the 
host response to the malignancy.  Circulating levels of biomarkers derived from these distinct 
sources are less likely to correlate and are thus more likely to offer complementary information 
leading to improved diagnostic utility.  Therefore, the evaluation of biomarkers conducted in the 
current investigation proceeded from a broad and diverse array of candidate proteins.        
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1.3 EXPERIMENTAL DESIGN  
1.3.1 Method Development 
The development of bead-based immunoassay platforms has had a significant impact on the field 
of serum biomarker discovery and development.  Such platforms represent a synergistic 
combination of the reproducibility and diverse utility of solid phase ELISAs with the improved 
kinetics and flexibility of a liquid-phase assay.  Bead-based systems also exhibit a high capacity 
for multiplexing which greatly reduces sample and reagent volume, conveys high throughput and 
automation capabilities, and permits the generation of large amounts of biomarker data in a 
single experiment.  The technique was first conceptualized by Streefkerk in 1976 66 leading to a 
patent filed in collaboration with Coulter in 1979.  Multiplexed assays, based on bead size and a 
flow cytometric analysis platform were introduced and implemented by McHugh 67-68 and 
Stewart 69 from 1989 through 1994.  Commercialization of the platform by Luminex Corporation 
(Austin, TX) in 1997 has ushered in the widespread usage of bead-based immunoassays for 
multiplexed biomarker analysis.  The general principles regarding the Luminex® platform are 
diagrammed in Figure 1.1.  Current protocols involve the use of a set of 5um microspheres 
internally labeled with a combination of two laser-reactive dyes.  Each of the dyes can be loaded 
into the bead at 10 levels of intensity, thus allowing for 100 spectrally-distinct microsphere lots.  
Following the covalent coupling of each microsphere lot to a capture antibody specific to a 
particular antigen of interest, beads of different spectral lots can be mixed together and utilized in 
a multiplex format.  The assay procedure then proceeds in a manner similar to that of traditional 
sandwich ELISA.  The bead mixture is incubated with patient sera and bound analyte is detected 
using a biotin-labeled antigen-specific polyclonal antibody.  The bead-coupled antigen/antibody 
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complexes are then fluorescently labeled using streptavidin-phycoerythrin (SA-PE).  The bead 
set is analyzed using one of several Luminex® analyzers, which incorporates flow cytometry-
based fluidics with dual-laser optics.  While one laser excites the internal bead dye combination, 
the other laser simultaneously excites the PE label.  The instrument then records and reports the 
identity of each bead, according to dye composition, along with the intensity of bound analyte, 
represented by PE fluorescence.    
 
Figure 1.1  Principles of the Luminex® platform Copyright 
 
 
 
 
 
 
A.  100 spectrally distinct bead lots are available for covalent coupling to distinct 
capture antibodies.  B.  Bead-capture antibody complexes are incubated with 
 sample.  Captured analyte is detected by biotin labeled polyclonal antibody and 
fluorescently tagged using SA-PE.  C.  Dual-laser excitation of sample permits 
the simultaneous determination of bead identity and quantitation of captured 
 analyte.  Copyright (c) 2011 Life Technologies Corporation.  Used under permission. 
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The current investigation required the assembly of an extensive multiplex array 
consisting of 65 separate xMAP assays for proteins relevant to epithelial carcinogenesis (Ch. 3, 
Table 3).  Commercially available xMAP assays do not include cancer antigens and many other 
important cancer biomarkers.  To expand the number of biomarker assays available on the 
Luminex® platform, additional multiplexed panels were developed in the laboratory.  
Laboratory-developed assays include: CA 19-9, CA 125, CEA, CA 15-3, ErbB2, EGFR, 
kallikrein 10, Cyfra 21-1, AFP, IGFBP I, full-length mesothelin, HE4, small mesothelin-related 
protein (SMRP), tissue transglutaminase (TgII), SSC, TTR.  These biomarkers have been 
multiplexed into six different panels, based on the absence of cross-reactivity and the required 
serum dilution factor.  These assays were developed and validated according to industry quality 
control standards regarding  sensitivity, inter- and intra-assay reproducibility, % recovery from 
serum, and correlation with conventional single analyte ELISA (when available) (Table 1.2).  
Monoclonal and polyclonal antibodies utilized in assay development were obtained from 
commercial vendors or collaborators and were evaluated individually for efficacy in the 
Luminex® platform.  Inter- and intra-assay variability, expressed as a coefficient of variation, 
was calculated based on the average of 10 patient samples measured on at least three separate 
occasions.  The performance of each assay was compared between single and multiplex formats 
to ensure the absence of cross-reactivity.   
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Table 1.2  Quality control characteristics of laboratory developed Luminex® immunoassays 
Assay Std Range Sensitivity % Recovery 
(Serum) 
Intra-
Assay CV 
(%) 
Inter-
Assay CV 
(%) 
ELISA 
Correlation 
(%) 
CA 19-9 .14-100 U/ml .02 U/ml 96 5 8.2 62 
CA 125 .69-500 U/ml .16 U/ml 87 4 9.55 98 
CEA .34-250 ng/ml .32 ng/ml 92 5 2.9 98 
CA 15-3 .27-200 U/ml .02 U/ml 114 4-5 7.12 97 
ErbB2 13.7-10000 pg/ml 23 pg/ml 50 3-5 9.28 99 
EGFR 137-100000 pg/ml 18.8 pg/ml 50 2-6 9.31 98 
Kallikrein 10 69-50000 pg/ml 52 pg/ml 52 3-6 11.22 NT 
Cyfra 21-1 137-100000 pg/ml 9 pg/ml 64 6 8.12 NT 
AFP 55-40000 pg/ml 3.2 pg/ml 140 2-7 9.22 NT 
IGFBP-1 13.7-10000 pg/ml 102 pg/ml 90 .7-5 6.68 NT 
Mesothelin 137-1000000 pg/ml 228 pg/ml 73 3-7 8.81 NT 
HE4 68-50000 pg/ml 68 pg/ml 88 5-8 12.95 60 
TTR 1.37-1000 ng/ml .8 ng/ml 85 4-8 9.59 NT 
 
Biomarker expression levels were expressed as median fluorescent intensities (MFI) 
generated by analyzing 50-100 microbeads for each analyte in a single sample.  The 
concentration of each analyte was quantitated from the MFI using standard curves generated by 
five-parameter curve fitting 70 to a series of known concentration standards.  The Mann-Whitney 
non-parametric U test was used to evaluate the significance of differences in serum biomarker 
levels between subject groups.  This test was chosen on the basis of robustness with respect to 
outliers, a common occurrence in the measurement of multiple serum biomarkers.  The 
multivariate analysis used in the development of multimarker panels was performed in close 
collaboration with Alexsey Lomakin, a statistician at the Massachussetts Institute of Technology.  
Dr. Lomakin has developed a bioinformatics algorithm that is specifically designed for the 
construction of descriptive multianalyte panels from serum biomarker data generated by 
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Luminex®.  This method, a Metropolis algorithm with Monte Carlo simulation (MMC) 1, 71-72 
constructs a Scoring Function (SF) for a specific biomarker panel from a linear combination of 
logarithms of biomarker concentrations.  The Monte Carlo optimization was then used to 
determine the coefficients in this linear combination that provides the highest sensitivity (the 
minimal number of misdiagnosed cases) at the desired specificity (fixed number of misdiagnosed 
control cases) in the case/control set.  The algorithm is designed to identify the best performing 
panels consisting of 2-5 biomarkers.  For each panel size, the panels with the highest sensitivity 
at the desired specificity are re-estimated for sensitivity by cross-validation.  For cross-
validation, 20% of subjects are randomly excluded from the data set and the rest used as a 
training set to build the optimal SF.  The resultant model is applied to the excluded subjects, and 
this process is repeated 400 times in order to obtain a smooth averaged ROC curve.  
1.3.2 Research Objectives  
The investigation detailed herein proceeded from the hypothesis that biomarkers present in the 
circulation of patients diagnosed with ovarian cancer and benign ovarian conditions can provide 
clinically relevant information pertaining to the development of malignancy and also a basis for 
the discrimination between the two conditions.  The evaluation of this hypothesis was conducted 
according to the following objectives:  i)  biomarkers levels present in the serum of patients 
diagnosed with several distinct histological subtypes of epithelial ovarian cancer and benign 
ovarian conditions were examined in order to identify alterations associated with specific disease 
pathology; ii)  biomarker levels present in the serum of a broad group of patients diagnosed with 
benign or malignant adnexal masses were examined in order to identify multimarker panels 
capable of discriminating the two conditions with high levels of sensitivity and specificity;  iii)  
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urine samples obtained from ovarian cancer patients, patients with benign ovarian conditions, 
and healthy controls were examined for biomarker levels to determine whether the use of urine 
as an analytical biofluid might offer advantages over serum with regards to diagnostic panel 
development.  The workflow associated with objectives i and ii is presented in Figure 1.2.   
Ovarian epithelial carcinoma can be subdivided into several distinct histological subtypes 
including clear cell, endometrioid, mucinous, and serous 2. These carcinoma subtypes may 
represent distinctive pathways of tumorigenesis and disease development 13, 21-22. This distinction 
could potentially be reflected in alterations of specific circulating biomarkers.  A broad array of 
circulating biomarkers was analyzed in sera obtained from a diverse set of patients diagnosed 
with ovarian carcinoma to identify trends and relationships associated with distinct carcinoma 
histotypes and divergent tumorigenic pathways.  Fifty-eight biomarkers including cancer 
antigens, oncogenes, cytokines, chemokines, soluble receptors, growth and angiogenic factors, 
proteases, hormones, and apoptosis and adhesion related molecules were evaluated using bead-
based immunoassays.  Nearly one-third of the biomarkers tested differed significantly between 
the cases and controls and a fair number of these alterations were subtype-specific.  The results 
demonstrate that the divergent histology-based tumorigenic pathways proposed for ovarian 
epithelial carcinomas are associated with distinct profiles of circulating biomarkers. Continued 
investigation into the relationships between these factors should reveal new insights into the 
complex mechanisms underlying ovarian epithelial tumorigenesis. 
The diagnosis of an adnexal mass is a prevalent issue among women in the United States 
while current methods of identifying those at high risk of malignancy remain insufficient 73-74.  
Ineffective triage of women with malignant masses is associated with delayed or inappropriate 
treatment and a negative effect on disease outcome 6.  Sixty-five ovarian cancer-related 
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biomarkers were examined in sera obtained from women diagnosed with an adnexal mass.  The 
subject group consisted of women diagnosed with benign masses and early and late stage ovarian 
cancer.  Over half of the biomarkers tested were found to differ significantly between benign and 
malignant cases.  As individual markers, HE4 and CA 125 provided the greatest level of 
discrimination between benign and malignant cases and the combination of these two biomarkers 
provided a higher level of discriminatory power than either marker considered alone.  
Multivariate statistical analysis identified several multi-marker panels that could discriminate 
early stage, late stage, and combined ovarian cancers from benign cases with similar or slightly 
improved SN/SP levels to the CA 125/HE4 combination, however these larger panels could not 
outperform the 2-biomarker panel in an independent validation set.  A 3-biomarker panel with 
particular utility in premenopausal women was also identified.  These findings serve to advance 
the development of blood-based screening methods for the discrimination of benign and 
malignant ovarian masses by confirming and expanding upon the superior utility of the CA 
125/HE4 combination.  
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Figure 1.2  Workflow for evaluation serum biomarkers and multimarker panels in ovarian cancer patients 
and women diagnosed with benign ovarian conditions. 
  
The measurement of biomarkers present in the bodily fluids of cancer patients represents 
an important avenue for the development of minimally invasive tests to predict tumorigenesis, 
disease recurrence, or treatment response.  A great deal of work along these lines has already 
been devoted to blood, given its systemic exposure and extensive availability through tissue 
banks.  However, blood is a dynamic biofluid with a proteome under continuous metabolic and 
homeostatic regulation.  Alternatively, urine represents a thermodynamically stable biofluid that 
is inherently quiescent in that all molecular and proteolytic activity is largely complete upon 
sampling 75.  The urine proteome, representing the direct product of renal filtration, provides a 
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testing matrix of far lower complexity relative to that of serum 76.  Thus, the use of urine as an 
alternative or companion to serum in biomarker analyses has recently been proposed 77.  An 
analysis of biomarkers present in the urine of patients diagnosed with ovarian cancer was 
performed utilizing multiplexed bead-based immunoassays.  Ovarian cancer patients were 
compared to healthy controls and women diagnosed with benign ovarian conditions.  Nearly all 
of the tested biomarkers were detectable in urine and many exhibited a greater diagnostic 
capacity in urine versus serum.  A multivariate analysis identified several urine multimarker 
panels capable of discriminating the cancer from the control groups with high sensitivity and 
specificity.  The use of a 4-biomarker panel comprised of 3 urine biomarkers and one serum 
biomarker resulted in the discrimination of ovarian cancer patients from healthy controls with a 
sensitivity of 99% at 95% specificity.  These results support the use of urine biomarkers as 
alternatives and/or companions to serum biomarkers for the early detection of ovarian cancer.         
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Abstract 
Objectives:  Ovarian epithelial carcinoma can be subdivided into separate histological 
subtypes including clear cell, endometrioid, mucinous, and serous.  These carcinoma subtypes 
may represent distinctive pathways of tumorigenesis and disease development.  This distinction 
could potentially be reflected in the levels of tumor produced factors that enter into the 
circulation and serve as biomarkers of malignant growth. Here, we analyze levels of circulating 
biomarkers from a diverse set of patients diagnosed with ovarian carcinoma to identify 
biomarker trends and relationships associated with distinct carcinoma histotypes and divergent 
tumorigenic pathways.     
Methods.  We utilize multiplexed bead-based immunoassays to measure serum levels of 
a diverse array of  fifty-eight biomarkers from the sera of patients diagnosed with various 
histological subtypes of ovarian carcinoma and benign lesions.  The biomarkers studied include 
cancer antigens, oncogenes, cytokines, chemokines, receptors, growth and angiogenic factors, 
proteases, hormones, and apoptosis and adhesion related molecules.  Levels of each biomarker 
are compared statistically across carcinoma subtypes as well as with benign cases.     
Results.  A total of 21 serum biomarkers differ significantly between patients diagnosed 
with ovarian carcinomas and benign cases.  Nine of these biomarkers are specific for carcinomas 
identified as clear cell, endometrioid, or mucinous in histology, while two biomarkers are 
specific for the serous histology.  In a direct comparison of the histology groups, ten biomarkers 
are found to be subtype specific.  Identified biomarkers include traditional and emerging tumor 
markers, cytokines and receptors, hormones, and adhesion- and metastasis-related proteins.   
Conclusions.  We demonstrate here that the divergent histology-based tumorigenic 
pathways proposed for ovarian epithelial carcinomas are associated with distinct profiles of 
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circulating biomarkers.  Continued investigation into the relationships between these factors 
should reveal new insights into the complex mechanisms underlying ovarian epithelial 
tumorigenesis.   
 
Keywords:  ovarian carcinoma; tumor histology; serum biomarkers; ovarian 
tumorigenesis   
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2.1 INTRODUCTION 
For women in the United States, ovarian cancer ranks eighth among cancers, excluding skin 
cancer, in terms of incidence, but moves up to fifth in a ranking of age-adjusted mortality 19.  
Ovarian carcinomas, tumors of the surface epithelium, are by far the most common form of 
ovarian cancer 13.  The notion that ovarian carcinomas arise from the surface epithelium or 
postovulatory inclusion cysts following chronic exposure to hormones is met with widespread 
agreement 78, however a growing number of clinicians and researchers are beginning to 
appreciate a far greater heterogeneity concerning the development of ovarian epithelial 
carcinoma (OEC).   Ovarian carcinomas can be classified into the histological subtypes of 
serous, clear cell, endometrioid, and mucinous which correspond to the different types of 
epithelia present in the female reproductive tract 79-80.   Serous tumors, which carry the poorest 
prognosis, are the most common form of ovarian carcinoma and make up roughly half of all 
diagnoses 81.  Serous tumors are histologically similar to cancers of the fallopian tube, and range 
from cystic papillary tumors to solid masses 81.  Endometrioid tumors, accounting for 15-20% of 
ovarian carcinomas, are characterized by endometrial-like glandular structures 82.  Mucinous 
tumors often contain cysts and glands lined by mucin-rich cells and constitute 10% of ovarian 
carcinomas 83.  Clear cell tumors represent 4-12% of ovarian carcinomas and are comprised of 
clear and hobnailed cells with an immature glomerular pattern 84.   
Within the broad spectrum of disease states represented by OEC, there is accumulating 
clinical, translational, and genetic evidence for the existence of two distinct classes of 
carcinogenesis 13.  These classes have been termed type I, tumors comprising low-grade serous, 
mucinous, endometrioid, malignant Brenner, and clear cell carcinoma, and type II,  tumors 
including high-grade serous carcinoma, malignant mixed mesodermal tumors (carcinosarcomas), 
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and undifferentiated carcinoma 13, 85.  Type I tumors typically present as early stage neoplasms 
that pursue an indolent course which may last more than 20 years 86-88.  Recent findings have 
traced the development of type I tumors through a stepwise series of well-described precursor 
lesions 85.  Benign cystadenomas and adenofibromas are believed to give rise to so-called 
borderline tumors which in turn develop into the type I tumors described above.  In contrast to 
type I tumors, type II tumors are not associated with any recognizable precursors and apparently 
develop de novo from the surface epithelium or inclusion cysts of the ovary 89.  Type II 
carcinomas present as late stage, high grade neoplasms that are clinically aggressive, evolve 
rapidly and metastasize early, and are associated with a poor prognosis 13, 88.  Type II tumors are 
relatively chemosensitive in comparison to type I tumors 13.      
Mutation screening and gene expression profiling have identified a number of molecular 
alterations and differences in gene expression that distinguish type I ovarian tumors from type II.  
These distinctions suggest a difference in prognosis and treatment response between the two 
groups 90-91.  Most prominent among observed genetic alterations are mutations in the BRAF and 
KRAS oncogenes, which occur in 28-35% of type I tumors but are largely nonexistent in type II 
tumors 92.  Mutations in the tumor suppressor gene PTEN and the CTNNB1 gene, which encodes 
β-catenin, are also more prevalent in type I tumors, particularly endometrioid carcinomas 93-95.  
Mutations in TP53 are common in type II carcinomas but relatively rare in type I tumors 96-100.  
Gene expression profiling and immunohistochemical analyses have identified numerous factors 
that are overexpressed in type II tumors when compared to type I including AKT2, human 
leukocyte antigen-G (HLA-G), apolipoprotein E, p53, MIB1, and bcl-2 101-104.     
Here we present an analysis of a diverse array of biomarkers found in the serum of 
women diagnosed with ovarian cancer.  Biomarker levels are compared among patients grouped 
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according to carcinoma subtype as well as with those presenting with benign disease to identify 
markers that may contribute to or result from a particular carcinogenic pathway.  In this manner, 
we seek to contribute to the evolving body of evidence related to ovarian epithelial 
tumorigenesis.   
 
2.2 MATERIALS AND METHODS 
2.2.1 Human Serum Samples 
Serum samples from 157 patients diagnosed with ovarian cancer as well as 130 women with 
benign ovarian lesions were provided by the Gynecological Oncology Group (GOG) (Cleveland, 
OH) without individual identification of patients.  Procedures for serum collection, processing, 
and storage have been previously described 105.  Written informed consent was obtained for each 
subject.  The diagnostic breakdown of the study population is presented in Table 2.1 and 
represents a diverse spectrum of disease subtypes.  Benign cases include a broad spectrum of 
non-malignant lesions representing a variety of histological origins.  Patients diagnosed with 
endometriosis were not included in this study.  Patients diagnosed with clear cell, endometrioid, 
and mucinous carcinomas are grouped together under the heading of “CEM Carcinoma.”   
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Table 2.1  Histological characteristics of subjects included in tumorigenesis study 
Diagnosis N Age Range 
Benign 133 24-87 
   
CEM Carcinoma 100 27-87 
     Clear Cell Carcinoma   24  
     Endometrioid Carcinoma 46  
     Mucinous Carcinoma 30  
   
     Stage I & II 83  
     Stage III & IV 17  
   
     Grade 1 17  
     Grade 2 11  
     Grade 3 16  
     Unknown Grade 56  
   
Serous Carcinoma  57 48-87 
     Stage I & II 27  
     Stage III & IV 30  
   
     Grade 1 2  
     Grade 2 21  
     Grade 3 29  
     Unknown Grade 5  
 
2.2.2 Multiplexed Bead-Based Immunoassay 
The xMAP™ bead-based technology (Luminex Corp., Austin, TX) permits simultaneous 
analysis of numerous analytes in a single sample.  Fifty-eight bead-based xMAP™ 
immunoassays for a variety of known or potential biomarkers for ovarian and other epithelial 
cancers were utilized in the present study (Table 2.2).    Assays were performed according to the 
manufacturers’ protocol or as described previously 105.  Samples were analyzed using the Bio-
Plex suspension array system (Bio-Rad Laboratories, Hercules, CA).  For each analyte, 100 
beads were analyzed and the median fluorescence intensity was determined.  Analysis of 
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experimental data was performed using five-parameter logistic curve fitting to standard analyte 
values.   
Assays for CA 19-9, CA 125, CA 15-3, CA 72-4, CEA, ErbB2, Kallikrein 10, EGFR, 
Cyfra 21-1, SMRP, tTG, HE4, osteopontin, transthyretin, and IGFBP-1 were developed in the 
UPCI Luminex® Core Facility 54.  The inter-assay variability of each assay was 5% to 11% and 
the intra-assay variability was 2% to 9%.  Assays for eotaxin, Mip-1β, IP-10, IL-2R, IL-1Rα, IL-
6R, DR5, TNF-R1, and TNF-R2 were obtained from Invitrogen (Camarillo, CA).  Assays for 
MMP-2, MMP-3, and MMP-9 were obtained from R&D Systems (Minneapolis, MN).  All other 
listed assays were obtained from Millipore (St. Charles, MO).  
  
Table 2.2  Biomarker array utilized in tumorigenesis study 
Category Individual Biomarkers 
Cancer Antigens/Oncogenes α-fetoprotein, CA 19-9, CA 125, CA 15-3, CA 72-4, 
CEA, ErbB2 
Cytokines/Chemokines/Receptors Eotaxin, fractalkine, GM-CSF, IFNγ, IL-10, IL-
12p70, IL-13, IL-1β, IL-1Rα, IL-2, IL-2R, IL-4, IL-5, 
IL-6, IL-6R, IL-7, IL-8, IP-10, MIF, MIP-1β, 
sCD40L, TNFα, TNF-R1, TNF-R2 
Growth/Angiogenic Factors EFGR, IGFBP-1, TGFα 
Proteases Kallikrein 10, MMP-2, MMP-3, MMP-9 
Hormones ACTH, FSH, GH, LH, prolactin, TSH 
Adipokines Adiponectin 
Apoptosis-related molecules Cyfra 21-1, DR5, sFas, sFasL 
Adhesion molecules sICAM-1, sVCAM-1, tTG, tPAI-1 
Other HE4, osteopontin, SMRP, transthyretin, MPO  
 
 
 27 
2.2.3 Statistical Analysis 
The Mann-Whitney nonparametric t test was used to evaluate the significance of differences in 
serum biomarker levels expressed as observed concentrations between patients diagnosed with 
benign ovarian lesions and various ovarian carcinoma subtypes.  The level of significance was 
p<0.05.   
2.3 RESULTS 
2.3.1 Analysis of Serum Biomarker Levels Across Ovarian Epithelial Carcinoma 
Subtypes 
Sera from patients presenting with clear cell, endometrioid, and mucinous carcinomas, hereafter 
termed (CEM), were considered jointly as this group was presumed to represent type I ovarian 
carcinomas.  Patients diagnosed with serous carcinoma presented with tumors that were almost 
uniformly high grade.  Thus, this group was presumed to represent type II carcinomas and was 
considered separately.  Serum biomarker levels from each of these groups were compared to 
each other as well as to those from patients diagnosed with benign ovarian lesions.  These results 
are presented in Table 2.3.     
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Table 2.3  Serum biomarker levels across ovarian epithelial carcinoma subtypes 
  Biomarker Levels (mean pg/ml ± 95% CI) Mann-Whitney Significance 
  Benign  
CEM 
Carcinoma 
Serous 
Carcinoma 
Benign 
vs. CEM 
Benign 
vs. 
Serous 
CEM vs. 
Serous 
CA 1251 14.15±4.61 49.65±15.04 123.9±51.17 *** ** *** 
CA 72-41 2.04±.285 13.5±7.9 4.39±2.06 *** 
 
** 
CD40L 19457±4732 23522±4994 16414±5929 
  
* 
Cyfra 21-1 891±222 2323±718 2633±886 *** ***   
EGFR 8548±344 7233±397 7552±636 *** **   
FSH2 37487±5344 24744±5182 36471±7751 
  
** 
HE4 5476±4357 74816±42866 43857±18512 *** ***   
IGFBP-1 10178±1891 15509±3660 9734±3536 
  
* 
IL-10 15.67±2.63 32.48±10.78 20.79±4.31 *** **   
IL-2R 355.7±57.2 541.6±105.2 651.6±169.8 *** ***   
IL-6 19.67±3.4 31.55±5.87 27.07±9.01 *** 
 
  
IL-7 8.5±.864 11.6±1.85 10.2±1.69 *** *   
IL-8 15±3.91 24.8±15.17 16.9±5.24 ** *   
IP-10 49.86±5.35 42.4±5.71 72.53±15.54 * *** *** 
LH2 19118±2435 15767±2982 22441±4496 ** 
 
** 
MMP-2 150963±8262 131903±9126 137652±14133 ** 
 
  
MMP-9 212302±34252 361810±62411 250084±64652 *** 
 
** 
MPO 91818±21710 123134±30713 80550±30403 * 
 
** 
SMRP3 44227±19250 43804±15896 117660±49778 
 
*** *** 
sVCAM-1 876645±68143 772258±66047 796917±70051 ** 
 
  
TgII4 9.44±1.38 14.34±1.61 14.95±3.09 *** ***   
TNF-R2 1515±137 1798±186 1836±228 * **   
tPAI-1 35876±3432 47987±4514 36723±4949 ***   ** 
1U/ml, 2IU/ml, 3pM, 4mU/ml  CEM: clear cell, endometrioid, mucinous carcinoma  * - p<0.05,  ** - p<0.01,  *** 
-p<0.001 
 
When the benign group was compared to the CEM carcinoma group, a number of 
significant serum biomarker level differences were observed.  Among the cancer antigens and 
oncogenes assayed, CA 125, CA 72-4, Cyfra 21-1, and HE4 were all elevated in the CEM 
carcinoma group while levels of EGFR were reduced in the same group.  The CEM carcinomas 
demonstrated higher levels of the cytokines IL-10, IL-2R, IL-6, IL-7, IL-8, and MPO as well as 
the cytokine receptor TNF-R2 in comparison to benign cases.  IP-10 was decreased among CEM 
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carcinomas.  Levels of MMP-2 were decreased among the CEM carcinomas while levels of 
MMP-9 were increased.  The CEM carcinomas also exhibited increased levels of tTG and tPAI-1 
and decreased levels of LH and sVCAM-1 when compared to the benign group.   
Serum samples from the serous carcinoma group were compared with the benign group 
and several significant differences were identified.  CA 125, Cyfra 21-1, HE4, and SMRP were 
elevated in serous carcinomas while levels of EGFR were reduced.  Among cytokines and their 
receptors, IL-10, IL-2R, IL-7, IL-8, IP-10, and TNF-R2 were all found to be increased in serum 
samples from serous carcinoma patients in comparison to the benign group.  Serum levels of LH 
and tTG were also increased in the serous carcinoma group.   
The CEM carcinoma group was compared to the serous carcinoma group to identify 
serum biomarker level differences.  Levels of CA 125 and SMRP were higher in the serous 
carcinoma group while CA 72-4 was higher in the CEM group.  The CEM carcinomas 
demonstrated increased levels of CD40L and MPO and decreased levels of IP-10 when 
compared to the serous carcinomas.  In the serous carcinomas, serum levels of MMP-9, FSH, 
and tPAI-1 were elevated while levels of IGFBP-1 were reduced in comparison to the CEM 
carcinoma group.     
2.4 DISCUSSION 
Tumorigenesis is a complicated and multi-faceted process that involves unchecked proliferation, 
immune evasion, angiogensis, stroma formation, tumor cell invasion  and migration, and 
implantation and growth within distant tissues.  To accomplish each of these feats requires a 
balanced and precise genetic background and tumor microenvironment, the components of which 
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remain largely unresolved by cancer researchers.  Here we attempt to identify circulating factors 
associated with ovarian epithelial tumorigenesis through the comparison of a broad array of 
serum biomarkers in patients with distinct ovarian carcinoma histotypes.   
The results of our analysis of serum biomarkers across OEC subtypes are outlined in 
Figure 2.1.  We identified nine biomarkers that were elevated in the serum of patients diagnosed 
with ovarian carcinoma regardless of the disease subtype.  These included the commonly used 
ovarian cancer biomarkers CA 125 and Cyfra 21-1 as well as the inflammatory cytokines IL-7, 
IL-8, and IL-10 and the receptors IL-2R and TNF-R2.  These same cytokines, known to promote 
growth and inhibit apoptosis 106, have been previously found to be produced in vitro by ovarian 
cell lines and primary cells 107-109 and have also been observed to be elevated in the sera of 
ovarian cancer patients in comparison to healthy and benign controls 110.  Also increased in our 
ovarian cancer group were HE4 and tissue transglutaminase (tTG).  HE4 is an 11kDa precursor 
to the epididymal secretory protein E4 and is an emerging biomarker for the detection of ovarian 
and endometrial cancer 111-113.  HE4 is overexpressed in ovarian carcinomas and demonstrates 
minimal gene expression and production in all tested normal tissues 57, 114.  tTG is highly 
expressed in ovarian tumors and has a proposed role in tumor invasion and migration by 
facilitating cell adhesion to fibronectin115.  tTG overexpression was most recently reported to be 
an adverse prognostic factor in ovarian carcinoma 116.  Our analysis found that serum levels of 
soluble EGFR were lower in ovarian cancer patients in comparison to benign cases.  Although 
cell surface EGFR is overexpressed in 35% to 70% of EOCs 117, it would appear from our 
investigation, and that of another group 38 that levels of the soluble form of EGFR present in 
serum are inversely correlated with ovarian cancer risk.   
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Figure 2.1  Serum biomarkers significant across ovarian epithelial carcinoma subtypes 
 
 
 
 
Our primary aim in this investigation was to identify biomarkers with distinct serum 
levels among presumed type I and type II OECs.  In comparison to benign pelvic disease, OECs 
of the clear cell, endometrioid, and mucinous (CEM) subtypes demonstrated significant 
differences in nine serum biomarkers while serous carcinomas differed among only two.  Among 
conventional tumor markers, our observations are in agreement with a previous study that found 
CA 72-4 to be highly specific for mucinous ovarian carcinoma while CA 125 was specific for the 
Findings presented in Table 3 are summarized.  Listed biomarkers were found to differ 
significantly between comparison groups.  Arrow preceding each biomarker name 
indicates increased or decreased serum concentrations in the cancer group.  A.  
Comparison between benign cases and ovarian cancer subtypes.  B.  Comparison 
between clear cell, endometrial, and mucinous (CEM) carcinomas and serous 
carcinomas.   
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serous subtype 118.  Two additional emerging ovarian cancer biomarkers, IGFBP-1 and SMRP, 
were also found to be subtype specific, an observation not previously reported.  Both of these 
markers have been implicated in ovarian cancer but remain uncharacterized 111, 119-120.  
Significant among the cytokines tested were IP-10 for serous carcinomas and IL-6 and sCD40L 
for CEM carcinomas.  These differences in serum cytokine levels were not as robust as those 
observed for all OECs considered together, suggesting a relative uniformity in tumor behavior.  
Interestingly, the CEM carcinomas demonstrated higher levels of myeloperoxidase (MPO).  
MPO is the chief protein product of neutrophils and is believed to play a role in the production of 
ROS and the oxidative activation of environmental carcinogens 121-122.  The results for the 
invasion, migration, and metastasis related molecules were somewhat mixed.  The CEM 
carcinomas demonstrated relatively high serum levels of tPAI-1 and MMP-9 and relatively low 
levels of MMP-2 and sVCAM.  Serous carcinomas did not differ significantly from the other 
groups for any of these markers.  This is intriguing in light of the clinical observation that serous 
carcinomas are the most aggressive subtype of OEC and metastasize far more readily.  Further 
investigation related to these observations would be justified.  The serous carcinomas 
demonstrated higher serum levels of the gonadotropins LH and FSH.  These hormones are 
important regulators of ovarian cell function and have been long implicated in the development 
of ovarian cancer, however the results from previous investigation concerning serum levels of 
the gonadotropins have been inconsistent 123.  The finding that LH and FSH play a greater role in 
the development of a particular histological subtype of ovarian carcinoma would be of great 
clinical significance.   
Circulating biomarkers found in the serum of ovarian cancer patients may represent 
factors involved in either the cause of or the systemic response to the malignancy.  These factors 
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may originate from a number of sources including the tumor itself, the surrounding stroma, or 
systemic tissues involved in the host response.  It is crucial that ongoing work in the field of 
serum biomarkers is aimed at pinpointing the origins and functional roles of identified 
biomarkers.  We sought to approach these questions by placing our findings within the broader 
context of genetic regulation of ovarian epithelial tumorigenesis.  To that end, we utilized the 
Ingenuity Pathway Analysis (IPA) software package (Ingenuity Systems Inc., Redwood City, 
CA) to identify published relationships between the biomarkers we found to be informative and a 
consensus list of genetic markers currently under investigation in the field.  A list of genes 
identified to be commonly mutated or overexpressed in CEM carcinomas includes: BRAF 85, 92, 
KRAS 85, 92, CTNNBI 94-95, PTEN 94, MAP3K 124, and PI3K 124.  This list was entered into the 
software package along with the list of biomarkers we identified when comparing CEM 
carcinomas with benign cases.  The IPA software identified relationships between molecules in 
the two groups as shown in Figure 2.2A.  A similar analysis was performed for biomarkers we 
identified in our comparison  of serous carcinomas with benign samples utilizing a list of genes 
including: AKT2 101, 125, APOE2 102, BCL2 104, HLA-G 103, MK167 104, TP53 96-100, and WT1 84.  
The results of this analysis are shown in Figure 2.2B.  Several of the genes examined are 
established players within molecular pathways widely considered to play a role in ovarian 
cancer.  Among these are the RAS/RAF/MAP pathway and the PI-3 kinase/PTEN pathway, both 
of which have been implicated in type 1 ovarian carcinomas 13, 124, and the p53 pathway active in 
type II carcinomas88.  The IPA analysis demonstrates that several of the serum biomarkers 
identified in this study have been reported to interact with members of these pathways and 
further study aimed at characterizing these relationships would be well warranted.      
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Figure 2.2  Ingenuity Pathway Analysis of identified serum biomarkers and reported molecular alterations 
 
 
 
 
 
 
This investigation clearly illustrates the unique and informative role of serum profiling in 
advancing our understanding of ovarian tumorigenesis.  Our findings suggest that several 
traditional and emerging tumor markers, factors involved in the host cytokine and hormonal 
response, and adhesion- and metastasis-related proteins may be differentially utilized among 
OEC histological subtypes.  An improved characterization of the mechanisms and molecular 
interactions that characterize the emerging pathways of ovarian epithelial tumorigenesis will 
allow for the development of improved tools and methods to better identify and capture every 
clinical opportunity.  
The Ingenuity Pathway Analysis software package (Ingenuity Systems Inc., Redwood City, 
CA) was used to identify relationships between identified  serum biomarkers and genetic 
markers associated with ovarian carcinoma subtypes. A.  Interactions identified between 
CEM carcinoma associated serum biomarkers and the following genes: BRAF, KRAS, 
CTNNBI, PTEN, MAP3K, and PI3K.  B.  Interactions identified between serous carcinoma 
associated serum biomarkers and the following genes: AKT2, APOE2, BCL2, HLA-G, 
MK167, TP53, and WT1.  Biomarker outlines:  green - increased in the serum of cancer 
patients, red – decreased in the serum of cancer patients.  Interaction labels:  A – activation, 
E – expression, PD – protein-DNA interaction, T – transcription, PP – protein-protein 
interaction, LO – localization, RB – regulation of binding, solid line – direct relationship, 
dashed line – indirect relationship. 
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Abstract 
Objectives:  The diagnosis of an adnexal mass is a prevalent issue among women in the 
United States while current methods of identifying those at high risk of malignancy remain 
insufficient.  Ineffective triage of women with malignant masses is associated with delayed or 
inappropriate treatment and a negative effect on disease outcome.  Methods:  We performed an 
evaluation of 65 ovarian cancer-related biomarkers in the circulation of women diagnosed with 
an adnexal mass.  Our subject group consisted of women diagnosed with benign masses and 
early and late stage ovarian cancer.  Results:  Over half of the biomarkers tested were found to 
differ significantly between benign and malignant cases.  As individual markers, HE4 and CA 
125 provided the greatest level of discrimination between benign and malignant cases and the 
combination of these two biomarkers provided a higher level of discriminatory power than either 
marker considered alone.  Multivariate statistical analysis identified several multi-marker panels 
that could discriminate early stage, late stage, and combined ovarian cancers from benign cases 
with similar or slightly improved SN/SP levels to the CA 125/HE4 combination, however these 
larger panels could not outperform the 2-biomarker panel in an independent validation set.  We 
also identified a 3-biomarker panel with particular utility in premenopausal women.  
Conclusions:  Our findings serve to advance the development of blood-based screening methods 
for the discrimination of benign and malignant ovarian masses by confirming and expanding 
upon the superior utility of the CA 125/HE4 combination.   
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3.1 INTRODUCTION 
According to current estimates, 1.4% of women born today, or 1 in 72, will be diagnosed with 
ovarian cancer at some point in their lifetime.  This year in the United States, there will be over 
21,000 new cases of ovarian cancer along with over 15,000 deaths. 126  These cases arise from a 
much larger group of women presenting with adnexal abnormalities.  The overall prevalence of 
adnexal abnormalities is estimated at 7% 73-74 and it is expected that 5-10% of American women 
will receive prophylactic surgery for suspected ovarian cancer at some point in their lives 74.  A 
pelvic exam is the primary clinical method by which adnexal masses are diagnosed and it is 
estimated that for each case of ovarian cancer identified, 10,000 pelvic exams will be performed 
73.  A patient’s age and menopausal status are important factors to consider upon the 
identification of an adnexal abnormality as the associated risk of malignancy increasess from 
13% in premenopausal women to 45% in postmenopausal women 127.     
While nearly all women diagnosed with ovarian carcinoma will initially present with an 
adnexal mass, only a small proportion of all masses detected will be malignant and the 
expeditious triage of these patients is the most important component of their treatment regimen.  
The burden of early identification of potential ovarian cancer falls predominantly upon the 
obstetrician/gynecologist whose training in the management of cancer patients is usually limited.  
While these practitioners can effectively manage the high percentage of patients diagnosed with 
functional cysts and benign neoplasms through observation and surgery, respectively 128-129, the 
clinical outcome for a patient presenting with a malignant mass can be drastically worsened if 
she is not immediately referred to a gynecological oncologist 6.  A series of diverse studies have 
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demonstrated a decrease in the relative risk of reoperation 130, and increases in disease-free 
interval 131 and overall survival 132 for women operated on by gynecological oncologists 
compared to gynecologists and general surgeons.  Despite these findings, referral rates remain 
disappointingly low for patients diagnosed with an adnexal mass 133.  Improvements upon current 
screening methodologies and the emergence of new techniques should aid general gynecologists 
in making appropriate referral decisions and thus, improve the effectiveness of ovarian cancer 
treatment.   
While useful in the identification of an adnexal mass, a pelvic examination is ineffective 
in discriminating benign and malignant lesions.  Transvaginal ultrasonography has proven useful 
as a secondary screening tool, however its utility as a screening tool remains questionable given 
its demonstrated low positive predictive value and clinically insufficient levels of sensitivity 134.  
Advanced imaging techniques such as CT or MRI have proven too expensive for widespread use 
given their limited SN and SP.  In addition to a family history, pelvic examination, and imaging, 
the CA 125 blood test is a standard component in the complete evaluation of an adnexal mass.  
Despite its widespread use as a biomarker, CA 125 has demonstrated disappointingly low SP and 
SN in all evaluated patient cohorts and particularly in pre-menopausal patients 135.  Although CA 
125 is associated with ovarian cancer in 80% of tested women over the age of 50, this association 
drops to less than 25% for women below that age 136.  The development of improved diagnostic 
screening tests for ovarian cancer is paramount in efforts to effectively triage patients presenting 
with an adnexal mass.  Recently, Richard Moore and collaborators, in an analysis of serum 
concentrations of CA 125, SMRP, HE4, CA72-4, activin, inhibin, osteopontin, epidermal growth 
factor receptor (EGFR), and ErB2 (Her2) from women undergoing surgery for an adnexal mass 
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demonstrated the clinical utility of a CA 125/HE4 combined test for the discrimination of benign 
and malignant ovarian masses with 76.4% SN at 95% SP 112, 137. 
  We performed an extensive analysis of 63 additional circulating proteins found in the 
serum of a large group of patients diagnosed with an adnexal mass.  Our objective was the 
identification of a biomarker panel that will surpass the CA 125/HE4 combination for 
discrimination of benign from malignant disease.   
  
3.2 MATERIALS AND METHODS 
3.2.1 Human serum samples   
The training and premenopausal sets consisted of serum samples obtained from four sources.  
Cancer patients were women with histologically diagnosed epithelial ovarian cancer, while the 
benign group consisted of women diagnosed with a spectrum of benign adnexal lesions.  Patients 
diagnosed with pelvic inflammatory disease (PID) were not included.  The complete diagnostic 
breakdown of the study population is presented in Table 3.1.  The training and validation sets 
consisted of postmenopausal women.  A distinct group of premenopausal patients was 
considered separately and a cutoff age of 48 was utilized to establish menopausal status.  FSH 
serum levels in women age 48-55, obtained during biomarker testing, were used to confirm 
menopausal status with levels >25mIU/ml indicating postmenopausal.  Procedures for serum 
collection, processing, and storage have been previously described 105.  Written informed consent 
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was received from each subject and protocols were approved by appropriate institutional review 
boards.   
 
Table 3.1  Clinical characteristic of study population included in adnexal mass study 
 Training Validation Premenopausal 
 N (%) Age Range 
(Median) 
N (%) Age Range 
(Median) 
N (%) Age Range 
(Median) 
Benign 141 (100) 48-88 (63) 140 (100) 48-84 (65) 18 (100) 15-47 (42) 
       
Histology       
  Mucinous 24 (17)  18 (13)   6 (33)  
  Serous 51 (36)  57 (41)  7 (39)  
  Other/Unknown 66 (47)  65 (46)  5 (28)  
       
Ovarian Cancer 264 (100) 48-87 (63) 169 (100) 48-86 (62) 58 (100) 27-47 (41) 
       
Stage       
   Stage I-II 132 (50)  63 (37)  31 (53)  
   Stage III-IV 132 (50)  106 (63)  27 (47)   
       
Histology       
   Clear Cell 26 (10)  11 (7)  4 (7)  
   Endometrioid 58 (22)  26 (15)  9 (16)  
   Mucinous 11 (4)  4 (2)  14 (24)  
   Serous 119 (45)  113 (67)  20 (34)  
   Other/Unknown 50 (19)  15 (9)  11 (19)  
 
3.2.2 Multiplex bead-based immunoassay   
The xMAP™ bead-based technology (Luminex Corp., Austin, TX) permits simultaneous 
analysis of numerous analytes in a single sample.  Sixty-five bead-based xMAP™ 
immunoassays for a variety of known or potential biomarkers for ovarian and other epithelial 
cancers were obtained and utilized in the present study (Table 3.2).  The training set was 
analyzed for the complete set of 65 biomarkers.  The premenopausal group was analyzed for a 
subset of 19 biomarkers chosen based on the results of the training set analysis and other 
published findings.  The validation set was analyzed for the most informative markers identified 
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in the training set.  Multiplexed assays, data acquisition, and analysis were performed according 
to the manufacturer’s protocol or as described previously 105.   
 
Table 3.2  Biomarker array utilized in adnexal mass study 
Biological groups Proteins Plex No. Source 
Inflammatory 
Mediators 
IP-10, TNFR I, II, IL-1R , IL-2R, IL-6R 
Eotaxin-1, interleukins 1b, 2, 4, 5, 6, 7, 8, 10, 
12p70, 13, GM-CSF, IFN-γ, TNF-α, MIP-1β, 
MIF, CD40L, fractalkine 
MPO  
1 
2 
 
 
8 
1 
2 
 
 
2 
Growth/angiogenic 
factors 
EGFR, Her2/neu  
IGFBP-1  
TGFα 
3 
4 
2 
3 
3 
2 
Tumor-associated 
antigens 
CA 125, CA 15-3, CEA, CA 19-9, CA 72-4  
AFP  
HE4 
3 
4 
12 
3 
3 
3 
Apoptotic proteins Cyfra 21-1 
DR5  
sFas, sFasL  
3 
1 
5 
3 
1 
2 
Proteases/Inhibitors Kallikrein 10  
MMP 2, 3, 9 
TIMPS 1-4  
tPAI-1 
4 
6 
7 
8 
3 
4 
4 
2 
Adhesion molecules sICAM, sVCAM  8 2 
Hormones prolactin, TSH, LH, ACTH, FSH, GH  9 2 
Adipokines Adiponectin  8 2 
Other markers Mesothelin  
SMRP  
Osteopontin, tissue transglutaminase 
apolipoprotein A1  
TTR, SCC  
4 
10 
11 
13 
14 
3 
3 
3 
2 
3 
Source No: 1 - Invitrogen/Biosource, Camararillo, CA;  2 - Millipore/Linco, St. Louis, MO;  3 – Luminex Core 
Facility, University of Pittsburgh, Pittsburgh, PA;  4 – R&D Systems, Minneapolis, MN 
Plex No. indicates multiplexed panel, i.e. biomarkers that were analyzed simultaneously 
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3.2.3 Statistical Analysis   
The Mann-Whitney U test was used to evaluate the significance of differences in serum 
biomarker levels expressed as observed concentrations between patients diagnosed with benign 
adnexal masses and ovarian cancer.  The minimum level of significance was p<0.05.  The 
multivariate analysis of the biomarker data was performed using the Metropolis algorithm with 
Monte Carlo simulation138.  All development of multivariate statistical models for distinguishing 
ovarian cancer cases from benign controls was restricted to the training set.  All possible panels 
consisting of 2, 3 and 4 biomarkers were evaluated for SN at 85% SP.  Optimal panels were 
chosen that offered high cross-validated SN for both early and late stage ovarian cancer and high 
specificity for benign pelvic disease.  These panels and method of combination were evaluated 
on the validation set to estimate, free from selection bias, the models’ SN and SP.  
Premenopausal cancer patients were considered without stage stratification due to the limited 
number of late stage cases.   
 
3.3 RESULTS 
3.3.1 Analysis of individual biomarker levels in benign and malignant adnexal 
masses   
Of the 65 biomarkers tested in the training set, 34 demonstrated significant differences between 
benign and malignant cases (Table 3.3).   Ovarian malignancy was associated with an increase in 
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circulating levels of 26 tested biomarkers and a decrease in levels of 8 biomarkers.  The 
comparison involving late stage ovarian cancer resulted in 33 biomarkers demonstrating 
significant differences, compared with 21 biomarkers for early stage cancer and 28 biomarkers 
for the combined set of cancer patients.  CA 125 provided the highest level of discrimination of 
benign from malignant cases among early stage tumors while HE4 performed best in the late 
stage disease group.   
 
Table 3.3  Serum biomarker levels across adnexal mass diagnoses for subjects in training set 
 
 
 
 
 
 
 Mean Biomarker Level (pg/ml │ p-value4) 
Biomarker  Benign All Cancer Stage I-II Stage III-IV 
ACTH 36.4 28.1 0.05 32.0 NS 22.1 0.01 
ApoAI3 2213 2088 0.01 2120 0.05 1858 0.01 
CA 19-91 0.130 0.347 0.001 0.315 0.001 0.471 0.001 
CA 1251 3.6 34.5 0.001 23.7 0.001 72.4 0.001 
CA-1531 0.49 0.83 0.001 0.66 0.01 1.06 0.001 
CA72-41 8016 11724 0.001 9874 0.001 14748 NS 
Cyfra 21-1 669 1421 0.001 1355 0.001 1840 0.001 
DR5 120 173 0.001 135 NS 294 0.001 
EGFR 19592 16902 0.001 18212 0.001 13713 0.001 
EOTAXIN 169.5 185.5 NS 161.5 NS 218.0 0.001 
ErbB2 1854 1948 NS 1791 NS 2412 0.001 
Fas 4152 4248 NS 4118 NS 4890 0.001 
HE4 2645 9621 0.001 5612 0.001 29779 0.001 
IGFBP-1 48784 40957 NS 58629 0.01 24078 0.001 
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Sera obtained from 76 premenopausal subjects were tested for 19 biomarkers chosen 
based on the results from the postmenopausal subjects and other published findings.  Eleven 
biomarkers demonstrated significant differences between cancer and benign cases (Table 3.4).  
CA 125 provided the highest level of discrimination of benign from malignant cases for any 
single biomarker evaluated in this group.  With the exception of eotaxin-1, all trends in 
biomarker levels between benign and malignant cases were consistent for the premenopausal and 
postmenopausal analyses, however the level of significance for many of the tested biomarkers 
was lower in premenopausal subjects, possibly a result of the smaller sample size.  Eotaxin-1 
was found to be significantly decreased in the sera of late stage ovarian cancer patients in 
Table 3.3 (Continued) 
IL-10 11.25 18.50 0.001 17.10 0.001 21.85 0.001 
IL-1Ra 1193 1288 NS 1035 NS 1751 0.01 
IL-2R 578 803 0.001 645 0.05 1401 0.001 
IL-6 15.85 24.05 0.001 21.25 0.01 31.95 0.001 
IL-7 8.01 10.50 0.001 10.20 0.001 11.65 0.001 
IL-8 8.41 12.45 0.001 11.20 0.01 14.95 0.001 
IP-10 78.4 79.7 NS 66.6 NS 106 0.001 
Kallikrein 10 47082 50163 0.001 48504 0.05 53054 0.001 
MMP-2 172917 152645 0.01 154843 0.05 150823 0.001 
MMP-9 184359 249059 0.01 241996 0.05 256590 0.01 
MPO 38480 59049 0.05 50142 NS 74169 0.01 
sFasL 43.75 29.60 0.01 36.05 NS 23.80 0.001 
sVCAM-1 821776 716309 0.05 721565 NS 700190 0.05 
TG II2 61.80 82.25 0.001 NA NT 
TIMP-1 104826 121653 0.001 NA NT 
TNF-a 6.69 7.23 0.001 6.88 NS 7.96 0.001 
TNF-RI 3090 4132 0.001 3410 0.01 5860 0.001 
TNF-RII 2240 2806 0.001 2590 0.01 3545 0.001 
tPAI 1 33723 42974 0.001 41068 0.01 49028 0.001 
Transthyretin 2273 1708 0.001 1921 0.01 1362 0.001 
1U/ml, 2mU/ml, 3ng/ml, 4 minimum level of significance determined by Mann-Whitney U test for 
comparison of cancer vs. benign;  NS – not significant, NT – not tested, NA – not applicable 
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comparison to benign cases for premenopausal subjects, the opposite of what was found in 
postmenopausal subjects.   
 
Table 3.4  Serum biomarker levels across adnexal mass diagnoses for premenopausal subjects 
  Mean Biomarker Levels (pg/ml | p-value3) 
 Benign All Cancer Stage I-II Stage III-IV 
CA 1251 3.37 43.75 0.001 37.40 0.001 63.00 0.001 
CA72-41 6.28 17.10 0.001 17.20 0.001 16.50 0.05 
Cyfra 21-1 0.71 59.90 NS 0.70 NS 643 0.05 
EGFR 16802 14841 0.001 15080 0.01 13974 0.05 
EOTAXIN 143 101.5 0.05 107 NS 91.1 0.05 
FSH2 8129 5155 NS 4143 0.05 10108 NS 
HE4 2180 5768 0.01 5904 0.05 4121 0.05 
IL-2R 478 699 0.01 692 0.05 773 0.05 
sV-CAM 688369 601087 NS 611459 NS 552433 0.05 
TNF-RI 2512 3216 0.01 3177 0.01 3337 NS 
tPAI 1 38178 51939 0.01 52048 0.01 50542 NS 
1U/ml, 2μIU/ml; 3 minimum level of significance determined by Mann-Whitney U test for comparison 
of cancer vs. benign biomarker levels 
NS – not significant 
 
3.3.2 Multivariate analysis of biomarker levels utilizing the MMC algorithm    
The classification performance for the best single, 2-, 3-, and 4-biomarker panels identified in 
our analysis are presented in Table 3.5.  The combination of CA 125 and HE4 was the best 
performing 2-biomarker combination of all studied 2-biomarker combinations (data for other 2-
biomarker combinations are not shown) classifying cancer from benign cases at a SP of 85% 
with a SN of 74.2% in early cancers, 91.7% in late cancers, and 83% in the combined group.  
This combination outperformed either CA 125 or HE4, considered individually, in all evaluated 
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disease classes.  Our analysis identified three 3-biomarker panels that demonstrated a 
classification power that was equal to or modestly better than the CA 125/HE4 combination in 
the training set.  Each of these panels contained the CA 125/HE4 combination along with a third 
biomarker: CEA, Cyfra 21-1, or EGFR.  The best 4-biomarker panel consisted of CA 125, HE4, 
CEA, and Cyfra 21-1 and demonstrated improved SN over the CA 125/HE4 combination in each 
disease class in the training set.  However, when applied to the validation set, each of the 
identified 3- and 4-biomarker panels performed at a level equal to but did not improve upon the 
CA 125/HE4 combination.   
 
Table 3.5  Biomarker panels that discriminate benign from malignant cases 
   Training Validation PreM 
Panel   SP SN ROC SP SN SP SN 
    All Early Late AUC  All Early Late   
CA 125   85 79.5 72.0 87.1 0.860 82.1 76.3 61.9 84.9 87.5 70.7 
HE4   85 70.5 50.8 90.2 0.835 84.3 83.4 69.8 91.5 93.8 43.1 
              
CA 125, HE4 85 83.0 74.2 91.7 0.868 77.9 89.4 79.4 95.3 87.5 62.1 
              
CA 125, HE4, CEA 85 83.0 73.5 92.4 0.872 77.1 90.5 82.5 95.3 87.5 63.8 
CA 125, HE4, Cyfra 21-1 85 84.1 76.5 91.7 0.875 79.3 85.8 71.4 94.3 81.3 69.0 
CA 125, HE4, EGFR 85 83.3 75.0 91.7 0.889 74.3 89.3 81.0 94.3 87.5 75.9 
              
CA 125, HE4, CEA, Cyfra 21-1 85 86.4 78.0 94.7 0.878 75.0 90.0 81.0 95.3 87.5 62.1 
All values (with exception of AUC) represent percentages (%); PreM: premenopausal subjects 
 
Each of the single and multi-marker panels identified in the analysis of the training set 
was subsequently applied to the set of premenopausal subjects (Table 3.5) as the small size of 
this group precluded any meaningful development of panels based on it alone.  In this group, CA 
125 alone provided the highest SN and SP at 70.7% and 87.5% respectively.  The addition of 
HE4 to CA 125 did not improve the SN and SP of the test, however a 3-biomarker panel 
consisting of CA 125, HE4, and EGFR did significantly improve the classification power, 
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demonstrating a SN of 75.9% at 87.5% SP.  None of the other identified multi-marker panels 
provided any appreciable improvement over CA 125 alone in the premenopausal group.   
 
3.4 DISCUSSION 
With the exception of highly invasive procedures such as biopsy and surgery, the 
evaluation of circulating biomarkers offers the most definitive means of distinguishing benign 
from malignant pelvic masses.  Several recent studies have evaluated various panels of 
circulating biomarkers in ovarian cancer patients and benign cases 62, 112, 139-141, however our 
study is the largest and most diverse to date to utilize biomarker profiles to discriminate between 
the two conditions.   Of the 34 descriptive biomarkers identified in our study (Table 3.3), 24 are 
in agreement with observations made in the above-referenced studies and the reader is referred to 
those works for a discussion of the proposed role of each biomarker in the development of 
ovarian cancer.  To the best of our knowledge, we are the first to describe significant differences 
in circulating levels of CA 15-3, Her2/neu, ACTH, DR5, sFas, sFasL, IGFBP-1, eotaxin-1, 
TNFRI, and kallikrein 10 in patients diagnosed with benign and malignant adnexal masses.  
Although most commonly associated with breast cancer, the tumor markers CA 15-3 and 
Her2/neu have both been previously implicated in the development of ovarian cancer  142-144.  
Secretion of the pituitary hormone ACTH has been observed in a number of ovarian tumors and 
cell lines and has been implicated in the development of Cushing’s syndrome among ovarian 
cancer patients in rare cases 145-146.  The apoptotic mediators DR5, Fas, and FasL have each been 
previously investigated in ovarian cancer resulting in the observations that elevated DR5 
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expression correlates with decreased overall survival 147, and the macrophage infiltrate in ovarian 
cancer expresses high levels of Fas and FasL 148.  Although specific roles for IGFBP-1, TNFRI, 
and Kallikrein 10 remain to be characterized, these biomarkers have all been shown previously 
to be associated with the development and progression of ovarian cancer 149-151.  The CC 
chemokine eotaxin-1 is an emerging biomarker for ovarian cancer with recently described serum 
level correlates and in vitro tumorigenic effects 152.   
The biomarker analysis described herein provides a revealing cross-section of the 
physiological conditions resulting from ovarian malignancy in comparison to benign disease.  
Further identification of the precise roles and origins of these biomarkers will greatly improve 
our understanding of ovarian tumorigenesis.  While the nature of our analysis does not permit 
such a complete characterization, we do provide a fairly comprehensive foundation for 
subsequent targeted biomarker studies.  An overview of our findings regarding individual 
biomarker levels is presented in Figure 3.1.  As shown in the heat map (Figure 3.1A), HE4 was 
the most highly elevated biomarker among cancer patients, followed by Cyfra 21-1, CA 125, and 
CA 19-9.  This observation is reflected in the inclusion of several of these markers in our most 
powerful discriminatory multimarker panels.  In the vast majority of cases, the magnitude of 
biomarker level changes, both up-regulated and down-regulated, was significantly more 
pronounced in late stage disease and for many biomarkers, the observed differences were 
significant in only the late stage patients.  These findings illustrate the challenges associated with 
the detection of early stage disease and the need to identify more informative biomarkers.  Aside 
from the preponderance of tumor-associated antigens near the top of the heat map, no 
appreciable trend in biomarker category distribution is apparent in this analysis.  Trends in 
biomarkers levels according to category are presented in Figure 3.1B.  The distribution reveals a 
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complex network of biological factors mediating inflammation, proliferation, apoptosis, and 
tissue remodeling at work during ovarian tumorigenesis.  Additional work aimed at further 
characterizing this biomarker network in terms of function and origin is underway in our 
laboratory and should add valuable insight to diagnostic efforts.   
 
Figure 3.1  Summary of biomarker changes observed in the sera of women diagnosed with benign and 
malignant adnexal masses 
 
 
 
 
A.  Biomarker Heat Map.  Values represent the percentage change over observed 
biomarkers levels in the benign group for the training set: 141 women with benign masses 
and 264 women diagnosed with ovarian cancer.  Values are based on results presented in 
Table 3.  Red indicates an increase in cancer levels over benign while green indicates a 
decrease.  The minimum level of significance in differences was p<0.05 by Mann-Whitney U 
test (values in italics were non-significant).  B.  Biological Trends.  Trends in biomarker 
level changes observed  in malignant versus benign masses are organized according to each 
biological category of biomarkers evaluated.   
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Our analysis reaffirms the superior utility of the CA 125/HE4 combination reported by 
Moore et al. for the diagnosis of ovarian cancer 112, 137 as this combination was able to 
discriminate cancer patients from benign cases with sensitivities ranging from 74.2% for early 
stages to 91.7% for late stages at 85% SP and was also included in each of the high performing 
3- and 4-biomarker panels we identified.  This observation is significant given the much larger 
array of biomarkers examined and the more diverse set of subjects with regard to disease stage 
and menopausal status utilized in our study.  The individual and combined sensitivities and 
specificities of CA 125 and HE4 observed here are very similar to those observed by Moore et al. 
112, 137 , as is the observation that the two biomarkers display diagnostic complementation as each 
improves upon the discriminatory power of the other.  In addition to CA 125 and HE4, we 
identified 3 other circulating biomarkers in our training analysis that offered at least modest 
improvement in discriminatory power when added to the 2-biomarker combination.  
Carcinoembryonic antigen (CEA) has been used to monitor colorectal cancer for decades and is 
reported to be elevated in 30-65% of ovarian epithelial cancers 153 although as an individual 
marker several limitations have been noted 154.  A fair amount of work has been devoted to the 
assessment of the Cyfra21-1 test in a variety of human cancers including lung 155, esophageal 156, 
head and neck 157, and cervical 158.  Recently, Baron et al. reported an increase in serum levels of 
Cyfra21-1 in ovarian cancer patients in comparison to benign cases and an association with 
disease stage 159.  Our findings regarding EGFR reaffirm those of several other groups in that 
lower serum levels of this marker are associated with ovarian cancer in comparison to benign 
cases 38, 112, 139.  Although the results of our validation analysis do not support the inclusion of 
CEA, Cyfra 21-1, and EGFR in a diagnostic panel at this time, our results further implicate these 
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biomarkers in the clinical development of ovarian cancer.  Future investigations utilizing 
additional refinements in screening methodology may uncover more precise roles for these 
biomarkers in the diagnostic setting.     
In our analysis of premenopausal subjects, we found that CA 125 alone provided the 
highest SN and SP, 70.7% and 87.5%, respectively, of any individual biomarker tested.  This 
runs counter to most current notions concerning a lack of specificity for CA 125 in 
premenopausal women.  One plausible explanation for this is the enrichment of CA 125 positive 
women in our limited patient set.  All of the women in this set were initially evaluated for an 
adnexal mass and CA 125 results would be expected to receive priority consideration in patients 
in this age group, for which malignancy is more uncommon.  Our finding that HE4 testing 
provided a lower SN than CA 125 and resulted in a reduced SN and SP when added to CA 125 
also disagrees with the findings of Moore et al 112.  However, such a comparison may not be 
valid given the considerable discrepancies in experimental design between the two studies and 
the relatively small number of patients studied.  Our premenopausal benign group was 
considerably smaller, 18 versus 82 subjects, and was compared to an age matched group of 
cancer cases that contained a high percentage of early stage disease.  In the study by Moore et al, 
the premenopausal benign group was compared to a combined group of cancer patients with a 
mean age of 65 years and only a small percentage of early stage disease.  The biomarker panels 
identified in our analysis of postmenopausal women were subsequently evaluated in the 
premenopausal group.  It should be noted that this approach may not be optimal given the 
demonstrated clinical and biochemical differences present in the two populations.  We chose this 
approach based on the small size of the premenopausal group, which prevented independent 
panel development, and also to evaluate the broader utility of our multimarker panels.  We 
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observed that a 3-biomarker panel consisting of CA 125, HE4, and EGFR provided the highest 
SN and SP of any single biomarker or combination in the premenopausal group.  This 
observation is significant in light of the recent findings of Baron et al. 38.  In that study, the 
authors conclude that decreased serum levels of EGFR represent a significant risk factor for 
ovarian cancer with particular relevance to younger, premenopausal women.  Thus, our findings 
expand upon the notion that EGFR may offer subset-specific clinical utility as a biomarker for 
the early detection of ovarian cancer.     
Here we report the identification and evaluation of several novel biomarker panels for the 
discrimination of benign from malignant cases in women diagnosed with an adnexal mass.  Our 
findings were the result of an extensive analysis of ovarian cancer related biomarkers in the 
serum of a diverse group of subjects, including a large number of both early and late stage 
patients.  Our results both corroborate and advance several recent reports regarding the 
importance of CA 125 and HE4 in this clinical setting and their combined use as a diagnostic 
test.  Continuing efforts to further characterize and implement these developments should lead to 
improved triage methodologies for women diagnosed with adnexal masses and a positive impact 
on overall disease outcome.   
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4.0  URINE BIOMARKERS OF OVARIAN CANCER 
4.1 INTRODUCTION 
Efforts to identify and validate biomarkers present in the bodily fluids of ovarian cancer patients 
are ongoing.  Investigators hope to utilize these findings in the development of minimally 
invasive tests to predict tumorigenesis, disease recurrence, or treatment response.  The bulk of 
this work has focused on blood, given its systemic exposure and extensive availability through 
tissue banks.  The analysis of blood, either through the use of serum or plasma, carries with it 
several inherent limitations which have hindered the development of clinically useful biomarker 
assays.  Foremost among these limitations is the relatively high level and complex nature of the 
protein repertoire found in blood.  Components of the blood matrix, including clotting and other 
serological factors, carrier proteins, immunoregulatory proteins, and active enzymes, all have the 
capacity to interefere with biomarker measurements.  The clotting process itself, employed 
during the preparation of serum, has been shown to involve enzymatic activity which results in 
the cleavage of unrelated proteins of interest 160-161.  The invasive nature of blood testing also 
limits accessibility to repeated measurements and presents a risk of infection to both the patient 
and healthcare professionals along with the added cost of minimizing this risk.        
Recently, urine has been proposed as an alternative biofluid for analytical biomarker 
studies on the basis that the systemic nature of such testing might be preserved while several of 
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the limitations inherent to blood testing could be eliminated.  Urine is available in larger 
quantities than blood through less invasive means, allowing for repeated measurements aimed at 
patient surveillance or establishment of assay reproducibility.  The urinary proteome is proposed 
to contain over 100,000 peptides, with 5000 of those present at high frequency 162, while studies 
have shown that this proteome is stable for hours at room temperature, days at 4˚C, and years at  
-20˚C 163.  The urinary proteome is a direct product of renal filtration and consists of low 
molecular weight, soluble peptides which are highly amenable to proteomic analysis and may 
represent disease specific cleavage processes 164.  Renal filtration also results in a less complex 
matrix than that of blood, containing fewer factors known to interfere with biomarker assays 76.  
The use of urine as a diagnostic biofluid does present unique challenges including a high 
variability in protein concentrations due to differences in fluid intake.  However, this barrier has 
been overcome successfully through normalization based on levels of creatinine or other 
common urinary peptides 165-166.  What remains in the development of urine-based analytical 
platforms is evidence that systemic disease-specific biomarkers are released into this biological 
compartment in a manner which can be reliable measured.   
Traditionally, investigations focused on urinary biomarkers have been limited to those 
related to disorders of the urogenital system, although it is estimated that only 70% of the urinary 
proteome originates from the kidneys or urinary tract with the remaining 30% resulting from 
glomerular filtration of blood plasma 167.  Urine, therefore, can be considered a systemic biofluid 
with expanded clinical applications.  A number of significant findings have been reported 
through the analysis of urine obtained from ovarian cancer patients.  Several early reports 
characterized the use of urinary gonadotropic peptide (UGP) as a general biomarker of 
gynecologic malignancy 168-170.  The combination of UGF and serum CA 125 proved particularly 
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useful in the diagnosis of ovarian serous carcinomas, providing a SN/SP of 86/89 169.  More 
recently, several other biomarkers including HE4 171, mesothelin 172, Bcl-2 33, and angiostatin 173 
were found to be differentially present in the urine of ovarian cancer patients and controls.  In 
their respective studies, urinary HE4 was found to discriminate ovarian cancer patients from 
controls at a level similar to that of serum HE4, while urinary mesothelin outperformed its serum 
counterpart.   Proteomic-based studies performed by several independent research groups have 
identified a number of additional urinary biomarkers and biomarker panels offering diagnostic 
potential for ovarian cancer 70, 76, 174-176.  Notable among these findings are a 3-biomarker panel 
which, in combination with CA 125, could discriminate malignant from benign pelvic masses 
with an AUC of .96 175, and the combination of glycosylated eosinophil-derived neurotoxin 
(EDN) and C-terminal osteopontin fragments which provided a SN of 94% at a SP of 72% for 
early stage ovarian cancer compared with benign controls 76.   
In the current study, urines obtained from a heterogeneous group of ovarian cancer 
patients, women diagnosed with benign ovarian disease, and a group of healthy control women 
were evaluated for levels of various biomarkers previously identified to be useful in several 
serum biomarker analyses.  Nearly all of the tested biomarkers were readily detectable in urine 
and many demonstrated highly significant alterations between the case and control groups.  
Several multiplexed urine biomarker panels were identified which provided a high level of 
discrimination between the groups.  Overall, these results demonstrated that certain urine 
biomarkers and multimarker panels are capable of outperforming similar serum-based tests for 
diagnostic purposes and the combined use of urine and serum biomarker testing may provide a 
superior means of patient classification.   
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4.2 MATERIALS AND METHODS 
4.2.1 Human Urine Samples 
Urines were collected from women diagnosed with epithelial ovarian cancer (n=109), benign 
ovarian or pelvic lesions (n=118), and healthy control women (n=72) seen at the University of 
Texas MD Anderson Cancer Center, Houston, TX (Table 4.1).  Women diagnosed with 
epithelial ovarian cancer underwent full surgical staging or tumor debulking as clinically 
indicated.  Benign subjects were women diagnosed with an ovarian cyst or pelvic mass, some of 
whom were scheduled to undergo surgical resection of the lesion.  All surgical tissues were 
examined by a gynecologic pathologist and final surgical pathology reports were obtained and 
recorded.  Healthy controls were women seen within the University Health System with no 
history of malignancy or other gynecological disorder and were included in the study based on 
age-matching.  Serum CA-125 measurements, performed using the Architect CA125II assay 
(Abbott Diagnostics, Abbot Park, IL) were obtained from women diagnosed with epithelial 
ovarian cancer (n=108) and benign lesions (n=101) as clinically indicated.  Serum CA-125 
measurements were also obtained from Healthy controls (n=61) when available.  All urines were 
collected prior to surgery or treatment.  Samples were collected and frozen at -80°C on the day of 
collection.  Written informed consent was received from each subject, and protocols were 
approved by the local institutional review board.  Urines were shipped frozen to UPCI for 
biomarker testing.  No more than two freeze/thaw cycles were permitted throughout the testing 
process.   
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Table 4.1  Patient characteristics for urine biomarker analysis 
 
4.2.2 Urine Biomarker Testing 
Each urine was tested for fifteen biomarkers chosen on the basis of previous performance in 
several serum-based biomarker analyses of ovarian cancer46, 177.  The tested biomarkers included: 
HE4, cytokeratin 19 (Cyfra 21-1), sEGFR, sErbB2, sIL-2R, sICAM-1, CEA, Eotaxin-1, 
sVCAM-1, CA 15-3, tPAI-1, CA 125, MMP-9, MPO, and CA 72-4.  Assays for sIL-2R, sICAM-
1, Eotaxin-1, sVCAM-1, and MPO were obtained from Millipore (Billerica, MA).  The assay for 
MMP-9 was obtained from R&D Systems (Minneapolis, MO).  All other assays were developed 
by the UPCI Luminex® Core Facility (Pittsburgh, PA) as described in Introduction section 1.3.1.  
All biomarker assays were performed according to manufacturer’s protocol or as described in 
Introduction section 1.3.1.  Urine creatinine measurements were determined for a subset of the 
study cohort using the PARAMETER Creatinine ELISA kit (R&D Systems, Minneapolis, MO), 
performed at the collection site.   
Group    Age  Histology  Stage  
Healthy  
N=72  
Range     49-85  
Median    62  
Average   59  
  
Benign 
N=118 
Range   47-86 
Median   62 
Average   61 
Non-malignant neoplasms (n=41) 
Benign cysts (n=36) 
LMP tumors (n=15) 
Other benign lesions (n=26) 
 
 
Cancer  
N=108  
Range     48-87  
Median    63  
Average   62  
Serous (n=72) 
Endometrioid (n=7) 
Mucinous (n=3) 
Mixed (n=19) 
Undifferentiated/Unknown (n=7) 
 
I (n=5) 
II (n=5) 
III (n=85) 
IV (n=13) 
LMP – low malignant potential 
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4.2.3 Statistical Analysis 
Individual biomarker levels were compared between the ovarian cancer and control groups using 
the Mann-Whitney non-parametric U test.  The False Discovery Rate was controlled at 5% using 
the method of Benjamini and Hochberg178.  After controlling, the minimum level of significance 
was p<0.04.  Reciever operating characteristic (ROC) curves were generated from the biomarker 
results using GraphPad PRISM (La Jolla, CA) and area under the curve (AUC) values were 
computed for the classification of ovarian cancers from controls.  The ROC AUC analysis was 
repeated in several previously collected and reported serum biomarker datasets 46, 177 for 
purposes of comparison.  The multivariate analysis of the biomarker data was performed using 
the Metropolis Algorithm with Monte Carlo simulation (MMC) (described in Introduction 
section 1.3.1).  Serum CA-125 results, obtained from the site of collection were included in this 
analysis.  All possible multimarker panels consisting of 2, 3, or 4 biomarkers were evaluated for 
sensitivity (SN) at fixed specificities (SP) of 95% (ovarian cancer vs. healthy subjects) or 90% 
(ovarian cancer vs. benign subjects).  These SP values were chosen in order to provide a basis for 
comparison with previous findings46, 177.  ROC curves and AUC values were generated for the 
top performing panels using GraphPad PRISM (La Jolla, CA).   
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4.3 RESULTS 
4.3.1 Individual Urine Biomarker Analysis 
The complete results for the individual analysis of urine biomarkers in ovarian cancer patients, 
benign subjects, and healthy controls are presented in Table 4.2.  Each of the 15 evaluated 
biomarkers were detectable in urine with the exception of CA 72-4.  The remaining 14 urine 
biomarkers all differed significantly in the comparison of ovarian cancer patients and healthy 
controls.  Of these, 11 were observed at elevated levels in the ovarian cancer group while 3 were 
decreased.  The most significantly altered urine biomarker in this comparison was HE4, followed 
by Cyfra 21-1, sEGFR, sErbB2, and sIL-2R.  Seven biomarkers differed significantly in the 
comparison of ovarian cancer patients and benign subjects, each of them observed at higher 
levels in the cases.  HE4 was also the most significantly altered biomarker in this comparison, 
followed by CA-125, sIL-2R,  and sVCAM-1.   
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Table 4.2  Urine biomarker levels in ovarian cancer patients and benign and healthy control subjects 
Biomarker Units Median  p-value† 
 
 
Healthy Benign Cancer  
Cancer vs. 
Healthy  
Cancer vs. 
Benign 
HE4      ng/ml 40.7 208.3 1897.7  2.21x10-26 (I)  2.11x10-25 (I) 
Cyfra 21-1 U/ml 1937.9 23087 28859.2  8.57x10-25 (I)  0.00073 (I) 
sEGFR     pg/ml 121.9 340.9 375.6  3.48x10-20 (I)  NS 
sErbB2    pg/ml 73.3 237.9 273.8  6.46x10-19 (I)  NS 
sIL-2R    pg/ml 176.15 251.1 547.5  9.24x10-18 (I)  3.39x10-11 (I) 
sICAM-1  pg/ml 1718.9 4200.3 5627.8  1.62x10-14 (I)  0.00030 (I) 
CEA  pg/ml 4655.6 1447.3 1079.4  2.5x10-14 (D)  NS 
Eotaxin-1  pg/ml 1.9 2.2 2.3  6.35x10-12 (I)  NS 
sVCAM-1  pg/ml 787.7 776.9 3811.6  1.48x10-11 (I)  1.18x10-10 (I) 
CA 15-3  U/ml 7.2 39.6 37.5  6.14x10-10 (I)  NS 
tPAI-1 pg/ml 5.5 5.8 5.9  2.50x10-9 (I)  0.03337 (I) 
CA-125  U/ml 1.4 1.3 5.7  3.61x10-9 (I)  5.53x10-15 (I) 
MMP-9    pg/ml 991.9 293.1 404.2  0.00119 (D)  NS 
MPO      pg/ml 5625 2262 2409  0.01548 (D)  NS 
†p-value determined by Mann-Whitney nonparametric U test , FDR controlled at 5% 
 
To evaluate the need to adjust individual biomarker levels based on factors such as fluid 
intake or kidney function, urine creatinine levels were determined in a subset of ovarian cancer 
patients (n=38) and healthy controls (n=29).  The distributions of creatinine levels within the two 
groups were markedly similar and the mean creatinine levels did not differ significantly (Figure 
4.1).  When the urine biomarker results were normalized based on creatinine levels in the 
evaluated subset, the statistical significance of each of the analytes listed above remained 
unchanged although a general elevation of p-values was observed (data not shown).   
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Figure 4.1  Urine creatinine levels in ovarian cancer patients and healthy controls 
 
 
4.3.2 Comparison of Urine and Serum Biomarkers 
Each of the 14 detectable urine biomarkers was evaluated for the capacity to discriminate cases 
from controls by ROC analysis.  The AUC values for each of these biomarkers was compared to 
those obtained in two previous studies of the same biomarkers measured in serum (Table 4.3, 
Figure 4.2).  In the comparison of ovarian cancer patients and healthy controls, 9 of the 14 
biomarkers demonstrated higher AUC values in urine vs. serum with completely non-
overlapping 95% confidence intervals (CI).  Two biomarkers, CA 125 and MPO, provided 
significantly greater AUCs in serum vs. urine.  The three highest performing individual 
biomarkers in either urine or serum were urine HE4, urine Cyfra 21-1, and urine sEGFR.  When 
the ovarian cancer group was compared to the benign group, sVCAM-1 and HE4 provided 
significantly higher AUC values in urine while sEGFR performed significantly better in serum.  
Urine creatinine levels were measured in a subset of ovarian cancer 
patients (n=38) and healthy controls (n-29) by ELISA.  Mean with 
95% confidence interval shown.     
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Urine HE4 was the most diagnostic biomarker out of any tested for this comparison, while the 
performance of CA 125 was nearly equivalent in both urine and serum.   
     
Table 4.3  Classification performance of individual urine and serum biomarkers 
Cancer vs Healthy (AUC (95% CI))†  Cancer vs Benign (AUC (95% CI))† 
 Urine Serum‡   Urine Serum* 
ErbB2    .892 (.844-.940) .530 (.396-.664)  sVCAM-1  .749 (.685-.812) .579 (.520-.639) 
sICAM-1  .834 (.780-.898) .525 (.419-.632)  sIL-2R    .757 (.693-.820) .651 (.597-.704) 
sEGFR     .906 (.864-.949) .605 (.535-.675)  HE4      .903 (.860-.946) .799 (.756-.841) 
CEA .836 (.777-.896) .551 (.494-.608)  sICAM-1  .640 (.567-.712) .555 (.493-.616) 
sIL-2R    .880 (.831-.928) .692 (.627-.758)  CEA  .573 (.498-.648) .532 (.476-.588) 
Eotaxin  .804 (.739-.868) .631 (.559-.702)  ErbB2    .550 (.475-.626) .532 (.476-.589) 
sVCAM-1  .798 (.734-.861) .628 (.566-.690)  CA 125  .802 (.744-.859) .799 (.754-.845) 
HE4      .970 (.949-.991) .858 (.805-.911)  Eotaxin  .518 (.442-.594) .516 (.459-.574) 
Cyfra 21-1 .954 (.924-.984) .860 (.819-.902)  MPO      .555 (.450-.630) .559 (.500-.619) 
tPAI-1 .763 (.692-.834) .675 (.612-.739)  Cyfra 21-1 .630 (.558-.703) .649 (.598-.700) 
CA 15-3  .774 (.702-.845) .822 (.741-.902)  MMP-9    .558 (.483-.634) .603 (.536-.670) 
MMP-9    .643 (.560-.726) .706 (.593-.819)  tPAI-1 .582 (.508-.657) .641 (.585-.696) 
CA 125  .760 (.692-.829) .905 (.866-.944)  CA 15-3  .556 (.478-.633) .648 (.594-.702) 
MPO      .607 (.521-.693) .830 (.739-.920)  sEGFR     .523 (.448-.599) .706 (.657-.754) 
†Determined by ROC analysis; Serum biomarker results based on analysis reported in ‡Yurkovetsky et al. JCO 
(2010)46 and *Nolen et al. Gyn Onc (2010)177; AUCs values in bold are significantly greater based on non-
overlapping 95% CI 
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Figure 4.2  Comparative performance of urine and serum biomarkers 
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4.3.3 Multivariate Analysis 
The MMC algorithm identified a number of urine biomarker panels which were capable of 
discriminating ovarian cancer cases from controls with high SN and SP (Table 4.4, Figure 4.3A).  
In the analysis of ovarian cancer patients and healthy controls, several 3-biomarker panels were 
identified which offered significant improvement over serum CA-125.  Each of these panels 
outperformed all possible urine 2-biomarker panels while the addition of a fourth urine 
biomarker did not result in an improvement in classification ability.  The highest performing 
three biomarker panel, comprised of u(urine)HE4, uCEA, and uCyfra 21-1, provided a SN of 
96% at a SP of 95%.  This panel also correctly classified 100% (n=10) of the stage I/II ovarian 
cancer cases.  Replacing uCyfra21-1 with either uEotaxin-1 or uCA 15-3 resulted in only small 
reductions in SN, while the replacement of uCyfra 21-1 with uEGFR caused a more significant 
decrease.  In order to investigate the efficacy of combining biomarker information from urine 
and serum, s(serum)CA-125 was combined with the urine biomarker panel of uHE4, uCEA, and 
uCyfra 21-1.  This combined urine/serum panel achieved a SN of 99% at a SP of 95% and was 
also 100% accurate in the identification of early stage disease.    
 
Table 4.4  Performance of multimarker panels for the discrimination of ovarian cancer patients from healthy 
and benign subjects 
Cancer vs. Healthy SN SP  Cancer vs. Benign SN SP 
uHE4,uCEA, uCyfra 21-1, sCA-125 99 95  uHE4, uCEA, sCA-125 85 90 
uHE4, uCEA, uCyfra 21-1 96 95  uHE4, sCA-125 84 90 
uHE4, uCEA, uEotaxin-1 94 95  uHE4, uCA-125 77 90 
uHE4, uCEA, uCA 15-3 94 95  uHE4 78 90 
uHE4, uCEA, uEGFR 91 95  sCA-125 71 90 
sCA-125 87 95     
Panels identified and characterized using Metropolis algorithm with Monte Carlo simulation (MMC); u – urine biomarker, s - 
serum biomarker 
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For the discrimination of ovarian cancer patients from benign subjects, a two biomarker 
panel consisting of uHE4 and uCA-125 performed optimally, providing a SN of 77% at a SP of 
95%, however this combination failed to outperform uHE4 alone.  When sCA-125 was 
substituted for uCA-125, SN was significantly improved to 84% (Table 4.4), although the ROC 
AUC of the panel was relatively unchanged (Figure 4.3B).  The addition of uCEA to this 
urine/serum combination resulted in only a minor improvement in SN.     
 
Figure 4.3  Top performing multimarker panels for the diagnosis of ovarian cancer 
 
4.4 DISCUSSION 
The topic of routine screening for ovarian cancer has received considerable attention from 
clinical researchers despite a high level of controversy.  Such controversy largely centers on the 
large number of false-positive test results associated with efforts to detect a condition of very 
low prevalence.  The result is a high degree of unnecessary treatment, invasive diagnostic 
testing, and patient anxiety.  The minimally acceptable positive predictive value (PPV) of 10% (1 
case identified for every 10 individuals tested) required for effective screening necessitates 
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diagnostic tools which provide a high level of SN and SP 31-32.  Currently used tools such as CA-
125 testing in blood and imaging procedures such as transvaginal ultrasound (TVS) have failed 
to perform to this standard 30.  A number of studies, including two large randomized control trials 
179-180, are currently investigating the combined use of CA-125 testing and TVS for screening 
purposes, however, improvements upon the individual performance of CA-125 are certainly 
needed for such a strategy to succeed.  Although many additional blood-based biomarkers for 
ovarian cancer have been identified and evaluated, little progress has been achieved in the 
development of diagnostic tests.  The current study demonstrates that several previously 
identified serum biomarkers of ovarian cancer provide greater levels of diagnostic utility when 
evaluated in urine.  The results of this preliminary analysis suggest that urine biomarker panels 
may provide levels of SN and SP for the discrimination of ovarian cancer patients from healthy 
controls approaching those required for routine screening.  The expanded use of urine as a testing 
matrix may not only result in the improved performance of previously identified biomarkers, but 
may also provide a basis for the identification of additional useful biomarkers, as in the study 
conducted by Ye et al 76.           
Each of the 14 urine biomarkers observed to be altered between cases and controls in this 
study have been examined previously within the setting of ovarian cancer.  The five biomarkers 
shown to be most useful with regard to diagnostic panel development: HE446, 137, 181, CEA46, 182, 
Cyfra 21-1159, 183, Eotaxin-1152, 184, and CA 15-3185, have all shown some promise as markers of 
early detection, prognosis, and disease monitoring.  Interestingly, CA 125, the most widely 
studied and utilized serum biomarker of ovarian cancer, was not found to be useful in urine.  
Urine CA 125 did not productively contribute to diagnostic panel development and the 
individual performance of serum CA 125 in the discrimination of ovarian cancer cases from 
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healthy controls significantly exceeded that of urine CA 125.  A plausible explanation for these 
observations stems from the considerable size of the CA 125 glycoprotein, estimated at 3-5MDa, 
and the estimated molecular weight cutoff associated with glomerular filtration, 30-50kDa.  CA 
125 was detectable in urine, suggesting that fragments of the molecule do indeed pass through 
the glomerulus in a form which can be recognized by the immunoassay, however the observed 
results indicate that cleavage processes responsible for such fragmentation are not reliable 
indicators of serum CA 125 levels.  Several other biomarkers included in this investigation are 
also relatively large, with molecular weights greater than 100kDa, including CA 15-3, sEGFR, 
CEA, sVCAM-1 and MPO.  A recent study examining the mechanisms of glomerular filtration 
concluded that in addition to molecular size, additional factors such as molecular conformation, 
charge, and deformability account for the ability of an individual molecule to be filtered 186.  The 
authors of that study demonstrate that molecules as large as 350-500kDa are rapidly cleared 
intact through the glomerulus.  Such a phenomenon may indeed play a role in the detection of 
protein biomarkers listed above, however is also likely that the observed urine biomarker levels 
represent specific proteolytic cleavage processes.  The latter notion is supported by the 
observation that several urine biomarkers including CA 125, EGFR, MMP-9, MPO, and 
sVCAM-1 exhibited differing trends among the cancer, benign, and healthy groups than their 
serum counterparts.        
The accurate and efficient triage of women presenting with a pelvic mass based upon risk 
of malignancy is a unique clinical setting in which diagnostic biomarker panels might provide a 
significant benefit in the short-term.  Effective and timely triage of this clinical group not only 
serves to reduce the number of invasive diagnostic procedures for the vast majority of those 
women whose masses are benign, but has also been shown to decrease morbidity and improve 
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overall survival through the referral of patients with malignancies to appropriately trained 
gynecological oncologists 6, 187-190.  Several recent reports investigating the efficacy of biomarker 
panels within this setting have identified the combination of CA 125 and HE4 as an effective 
diagnostic tool capable of discriminating benign from malignant pelvic masses with high SN and 
SP 112, 177.  This combination later demonstrated efficacy in a prospective study 137 and was 
subsequently incorporated into a scoring model termed the Risk of Ovarian Malignancy 
Algorithm (ROMA) 191.  In the current study, the combination of urine HE4 and serum CA 125 
was optimal for the classification of ovarian cancer patients and benign controls.  As was the 
case in the comparison of ovarian cancer patients and healthy controls, the use of urine CA 125 
was not beneficial.  Here, uHE4 outperformed sHE4 on an individual basis in both group 
comparisons and the SN and SP of the uHE4/sCA 125 panel in this study is superior to that of 
sHE4, sCA 125 in a previous study 177.  In a separate similarly designed study, uHE4 was 
reported to perform at a level on par with sHE4 171, however the sampling sizes used in that 
study were considerably smaller than those here.  Indeed, additional work aimed at the 
differential use of the HE4 biomarker is warranted. 
 An investigation into the potential benefits of urine as an analytical biofluid for 
biomarker development demonstrated that the diagnostic utility of a number of previously 
identified serum biomarkers of ovarian cancer was augmented upon testing in urine.  The study 
design does have several limitation which should be addressed going forward.  The benign 
subject group contained a small number of women diagnosed with low malignant potential 
(LMP) tumors and endometriosis.  While these conditions reflect distinct pathologies which may 
serve to confound biomarker experiments, their presence within this control group is indicative 
of the clinical setting under investigation.  Additional biomarker studies focusing particular 
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attention upon these groups should further refine efforts to properly triage these patients.  It 
should be noted that nearly all of the LMP tumors were classified as “cancer” by the uHE4, sCA 
125 model.  Such a classification appears most prudent at this time.  This investigation was also 
limited by the small number of early stage cases included.  While the best performing model of 
uHE4, uCEA, and uCyfra 21-1, with or without the inclusion of sCA 125, correctly classified 
100% of the stage I/II ovarian cancers, additional studies utilizing larger cohorts of early stage 
patients will be needed to further demonstrate the efficacy of urine biomarker panels.  In 
conclusion, urine biomarkers used as an alternative to or in combination with serum biomarkers 
offer a minimally invasive and effective means of ovarian cancer detection.       
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5.0  SUMMARY AND CONCLUSIONS 
5.1 BIOMARKERS AND TARGETED THERAPIES FOR OVARIAN CANCER 
5.1.1 Introduction 
Throughout the course of the last three decades, the incremental optimization of surgical 
techniques and chemotherapeutic regimens has achieved a meaningful impact on the overall 
management of ovarian cancer.  The current standard-of-care use of combination carboplatin and 
paclitaxel as a first-line therapy now yields response rates of over 80%, with complete response 
rates of 40-60% 192-198.  Despite these advances, current treatment regimens remain characterized 
by disappointment due to a failure to extend progression-free survival in advanced patients, a 
persistently high rate of relapse following first-line therapy, and an overall inability to produce a 
cure at diagnosis 195, 199.  Thus, the identification and development of targeted therapies has 
moved to the forefront of ovarian cancer research.  A number of promising therapeutic targets 
have been identified in recent years, with a large number of clinical trials initiated (Table 5.1).  
Novel drugs, in the form of monoclonal antibodies and small molecule inhibitors, are under 
development which target specific components of the multiple molecular pathways shown to 
play a role in the development of ovarian cancer.  The high degree of biological heterogeneity 
which characterizes ovarian cancer, wherein the dysregulated tumorigenic pathway varies on an 
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individual basis, has hindered the clinical impact of targeted therapies and emphasizes the need 
for improved tools aimed at identifying those patients most likely to benefit from a particular 
treatment.   
 
Table 5.1  Recent, ongoing, and planned clinical trials of targeted agents in ovarian cancer 
Agent Target Class Phase Clinical Trials 
Bevacizumab VEGFA Monoclonal Antibody I-III 14 
Aflibercept VEGF Inhibitor  II 1 
Sunitinib VEGFR Inhibitor II 1 
Cediranib VEGFR Inhibitor II-III 3 
Sorafenib VEGFR, PDGFR, c-Kit Inhibitor I-II 5 
Pazopanib VEGFR Inhibitor II-III 2 
Cetuximab EGFR Monoclonal Antibody II 3 
Matuzumab EGFR Monoclonal Antibody II 1 
Erlotinib EGFR TK Inhibitor I-III 5 
Gefetinib EGFR TK Inhibitor II 5 
Trastuzumab ErbB2 Monoclonal Antibody II 1 
Olaparib PARP Inhibitor II 2 
Farletuzumab α-FR Monoclonal Antibody II 1 
 
The findings presented in chapter 2 of this dissertation provide evidence that serum 
biomarker profiles can provide information regarding the histological subtype of epithelial 
ovarian cancer.  Previous findings aimed at characterizing these disease subtypes have revealed a 
number of distinct molecular alterations and differential clinical behavior associated with each of 
these subtypes.  A bioinformatic pathway analysis of the results presented in chapter 2 revealed a 
number of experimentally defined links between the current biomarker findings and previously 
reported molecular alterations.  Taken collectively, this work suggests that serum biomarkers 
may serve as effective tools in the identification of specific patients and groups of patients likely 
to benefit from a given type of targeted therapy for ovarian cancer.  A detailed and informed 
analysis of serum biomarkers could not only provide information regarding the histology of the 
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disease, but also the specifically dysregulated biological pathways underlying the development 
of that disease.  In the following sections, several of the most promising avenues for targeted 
therapeutic development in which there is an unmet need for improved patient selection are 
discussed. 
5.1.2 Targeting tumor angiogenesis 
The process of angiogenesis is a critical element in the development of virtually all types of solid 
tumors.  The formation of new blood vessels through angiogenesis is required for tumor growth 
beyond 1-2mm and the initiation of this process often marks a transition from tumor dormancy to 
full malignancy 200-201.  Although the process of angiogenesis represents a complex and highly 
regulated series of mechanisms, several prominent players, namely the vascular endothelial 
growth factor (VEGF) family and its receptors (VEGFR1-3), have been identified 202.  These 
factors have served as targets for therapeutic development in a number of malignant settings, 
with anti-angiogenic agents currently moving from Phase II to Phase III clinical trials in ovarian 
cancer 203.   
The most intensely evaluated anti-angiogenic agent is Bevacizumab, a recombinant 
humanized monoclonal antibody directed against VEGFA.  Bevacizumab has been evaluated in 
several clinical trials of ovarian cancer with response rates ranging from 16-21% and a six-month 
progression-free survival (PFS) of 40.3% 204-205.  Two  large randomized trials (GOG 218, ICON 
7) of Bevacizumab as a first line therapy in combination with carboplatin and paclitaxel are 
currently underway with the aim of assessing PFS in comparison to chemotherapy alone.  Other 
types of anti-angiogenic agents currently in clinical trials in ovarian cancer include VEGF trap 
(Aflibercept) 206, a fusion protein consisting of the VEGF binding domains of VEGFR1/2 and the 
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Fc region of IgG, and several small molecule inhibitors of receptor tyrosine kinases association 
with VEGF signaling: cediranib, sunitinib, sorafenib, and pazopanib 207-211.   
Several studies have identified subtype-specific properties of angiogenesis within the 
setting of ovarian cancer.  These findings indicate that agents targeting VEGF or VEGF 
signaling may be particularly useful in the treatment of ovarian clear cell and mucinous 
carcinomas 212-213, however much additional work is needed in order to further define the 
differential use of angiogenic mechanisms.  Biomarkers which convey information regarding the 
reliance of individual ovarian tumors or tumor subtypes on specific VEGF receptor/ligand 
interactions and downstream signaling events would greatly enhance the effectiveness of anti-
angiogenic agents.   
5.1.3 Targeting the EGFR family 
The epidermal growth factor receptor (EGFR) family and its ligands have well-documented roles 
in the development of ovarian cancer (reviewed in 144).  As such, a number of agents targeting 
EGFR have been developed and evaluated in ovarian cancer.  These include several monoclonal 
antibodies directed against the receptor itself (cetuximab, panitumumab, and matuzumab), and 
also several small molecule tyrosine kinase inhibitors (erlotinib and gefitinib).  The efficacy of 
each of these agents in clinical trials has been extremely limited 214-228.  Differential levels of 
soluble EGFR in the sera and urines of ovarian cancer patients and controls were noted in each 
of the studies presented in this dissertation and the diagnostic potential of serum EGFR in 
ovarian cancer has been reported previously 38, 46.  While additional work is necessary in order to 
characterize the relationship between circulating levels of EGFR and EGFR-dependence in 
tumors, further examination into the predictive value of circulating EGFR with regard to EGFR-
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targeted therapy appears warranted.  Likewise, while the results of Chapter 2 indicate no 
significant difference in EGFR levels between Type I and II ovarian carcinomas, additional 
studies focusing on individual carcinoma subtypes may yield more informative results.                        
An additional member of the EGFR family, ErbB2, is an important tumor marker in 
breast cancer and is also overexpressed in a subset of ovarian cancers 144.  The ErbB2-directed 
monoclonal antibody trastuzumab (Herceptin) has been evaluated in ovarian cancer with modest 
efficacy 229.  In the current set of studies, serum levels of sErbB2 were significantly increased in 
ovarian cancer patients and this increase was more apparent in urines.  Additional serum or 
urine-based studies evaluating the predictive properties of this biomarker would be warranted.  
ErbB2 may be particularly overexpressed in mucinous ovarian carcinomas, indicating a potential 
avenue for improved efficacy 230.     
5.1.4 PARP inhibitors 
The Poly-ADP-ribose polymerase (PARP) proteins have emerged as popular targets for 
anticancer therapy given their documented roles in several oncogenic pathways including cell-
cycle control, cellular differentiation, and DNA repair 231.  Treatment with PARP inhibitors leads 
to the accumulation of single-strand DNA breaks in tumor cells 232, and this observation has 
prompted the clinical investigation of these agents within the setting of BRCA1/2-related ovarian 
cancer.  Previous work has shown that tumor cells harboring mutations in the BRCA genes are 
highly sensitive to PARP inhibitors, likely due to the DNA double strand break repair 
deficiencies displayed by those cells 233.  The PARP inhibitor olaparib has demonstrated a dose-
dependent high response rate in a phase II trial of this type 234.   
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Phenotypic similarities between BRCA-associated ovarian tumors and high-grade serous 
tumors, type-2 ovarian carcinomas, suggest the expanded use of PARP inhibitors in this subtype 
of sporadic disease 235.  Indeed, several studies have reported the loss of function of a number of 
DNA-repair pathway related proteins, including BRCA1/2 in high grade serous tumors 236-237.  In 
light of these findings, the targeting of type 2 ovarian carcinomas through the aid of specific 
biomarkers for treatment with PARP inhibitors may prove effective.  
5.1.5 Additional targets 
The alpha folate receptor (α-FR) is expressed on over 70% of primary and 82% of recurrent 
ovarian tumors 238.  Expression of α-FR is particularly high in non-mucinous carcinomas and 
correlates with tumor grade, suggesting the potential for subset targeting.  A monoclonal 
antibody to α-FR, farletuzumab, has shown promising activity in preclinical and clinical studies 
239-240. 
The insulin-like growth factor (IGF) family of proteins represents an important group of 
regulators of cell proliferation and survival.  Members of this family have emerging roles in 
carcinogenesis and tumor progression and are the targets of novel therapeutic development 241-
245.  Several IGF-related proteins have been evaluated in serum as potential biomarkers of 
ovarian cancer 46, 62, in addition to the evaluation of IGFBP-1 within this current study.  A 
monoclonal antibody directed against the IGF-1 receptor, AMG 479 has demonstrated potent 
inhibition of the PI3-Akt pathway in xenograft mouse models of pancreatic cancer and also 
enhances the anti-tumor effects of several anti-EGFR targeted agents 246.  Clinical trials 
involving AMG 479 in ovarian cancer are planned.   
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Activation of the PI3-Akt pathway in ovarian cancer appears to play an important role in 
ovarian carcinogenesis and my represent a mechanism of resistance to therapies targeting the 
EGFR signaling axis 221, 247.  AKT2 alterations are prominent in ovarian tumors, particularly in 
the more aggressive type II carcinomas 101, 125, while mutations in PI3k have been associated 
with endometrioid ovarian carcinomas 248.  These observations indicate that careful targeting will 
be required to achieve an optimal therapeutic impact for these targets.  A number of inhibitors of 
PI3k and Akt family members (rapamycin, temsirolimus, everolimus, deforolimus) have shown 
promising preclinical results and are now entering phase I clinical trials 249.                   
5.2 BIOMARKER PANELS AS SCREENING TOOLS FOR OVARIAN CANCER 
5.2.1 Introduction 
The development of multimarker panels for the diagnosis of ovarian cancer is currently 
advancing on two fronts.  The first of these fronts includes investigators seeking improved tools 
for use in screening strategies for ovarian cancer in the general population.  Given the limited 
performance of currently used imaging techniques and CA 125 testing as well as the overall 
rarity of ovarian cancer, routine population-based screening is not recommended by any of the 
major relevant professional societies 250.  It also remains unlikely that any standalone biomarker-
based screening test will be capable of overcoming the 10% PPV level required for 
implementation.  However, work has persisted based on the notion that biomarker testing may 
prove effective in sufficiently defined high risk groups or as part of a multimodal screening 
strategy involving TVS or an equivalent imaging method as a second-line test.  The second front 
 78 
in the clinical use of ovarian cancer biomarkers pertains to the use of multimarker panels in the 
triage of women presenting with a pelvic mass.  Effective and timely triage of this clinical group 
not only serves to reduce the number of invasive diagnostic procedures for the vast majority of 
these women with benign masses, but has also been shown to decrease overall morbidity and 
improve overall survival through the referral of patients with malignancies to appropriately 
trained gynecological oncologists within specialized centers of excellence 6, 188, 190.   
The findings described in Chapters 3 and 4 of this dissertation represent important 
measures of progress within each of the developmental fronts outlined above.  The identification 
of several biomarker panels useful in the discrimination of benign and malignant pelvic masses, 
including the optimal performance of the CA 125/HE4 combination, is an advancement upon 
previous findings within this clinical setting and a foundation for ongoing work.  The results 
presented in Chapter 4 demonstrate the potential for improved performance of biomarker-based 
screening tests through the use of urine.  Further advancement along these lines should bring 
such screening tests closer to widespread implementation.  Recent efforts in the development of 
biomarker-based screening tools are discussed in this section.       
5.2.2 Biomarker panels for routine screening 
Despite the lofty performance standards currently in place for ovarian cancer screening tests, a 
number of research groups have reported findings which offer considerable promise and warrant 
further attention (Table 5.2).  Perhaps most notable among these reports is that of a six-
biomarker panel comprised of CA 125, leptin, prolactin, osteopontin, IGF-II, and macrophage 
inhibitory factor (MIF) which offered 95.3% SN at 99.4% SP in the discrimination of ovarian 
cancer patients from healthy controls 62.  Following a high level of initial enthusiasm and the 
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subsequent marketing of this panel under the trade name OvaSure, a number of deficiencies in 
study design have been identified which illustrate the challenges facing biomarker development 
efforts in general.  Most prominent among these deficiencies was the drastic overestimation of 
PPV based on inaccurate calculation of ovarian cancer prevalence 251-252.  This observation 
coupled with the lack of evaluation in a large prospective study led to performance revisions and 
the withdrawal of the commercial kit.  In a recent report, our group sought to more adequately 
address the issue of disease prevalence by utilizing a subject cohort which included more than 
2000 healthy women 46.  While it should be noted that our cohort included only postmenopausal 
women and the prevalence of ovarian cancer within the cohort remained elevated with respect to 
the general population, our identified panel of CA 125, HE4, carcinoembryonic antigen (CEA), 
and vascular cell adhesion molecule-1 (VCAM-1) was found to discriminate early-stage ovarian 
cancer from the control group with 86% SN at 98% SP.   
 
Table 5.2  Multimarker panels which discriminate ovarian cancer cases from healthy controls. 
Panel Cases Controls SN SP Reference 
CA 125, leptin, prolactin, osteopontin, IGF-II, MIF 156† 362† 95.3 99.4 Visintin et al.62 
CA 125, HE4, CEA, VCAM-1 456† 2000† 86-93 98 Yurkovetsky et al.46  
CA 125, HE4, Glycodelin, Plau-R, MUC1, PAI-1 200 396 80-89 87 Havrilesky et al. 253 
CA 125, CRP, SAA, IL-6, IL-8 150† 212† 94.1 91.3 Edgell et al. 254 
CA 125, HE4, SI* 74 137 84 98.5 Andersen et al. 255 
CA 125, TTR, ApoA1 200 82 89 92 Su et al. 256 
CA 125, IL-6, IL-8, VEGF, EGF 44 45 85 95 Gorelik et al. 105 
CA 125, ApoA1, TTR, H418 200† 142† 74 97 Zhang et al. 65 
CA 125, CA 72-4, M-CSF 123† 224† 70 98 Skates et al. 60 
*Symptom index; †includes independent validation set 
 
In Chapter 4 of this dissertation, it is demonstrated that three of the four biomarkers 
included in the panel above (HE4, CEA, and VCAM-1) provide a greater level of discrimination 
in urine compared to serum.  While a direct comparison of similarly designed urine and serum 
biomarker panels has yet to be performed, the current results indicate that a urine panel of this 
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type may offer superior performance.  An expanded analysis of urine biomarkers, including 
several found to be useful in serum by other groups, appears to be warranted.  For example, a 
panel derived from plasma was recently found to perform well in the discrimination of early 
stage ovarian cancer with a reported SN of 94.1% at a SP of 91.3% 254.  Here, CA 125 was 
combined with the inflammatory cytokines IL-6 and IL-8, and the acute-phase proteins C-
reactive protein (CRP) and serum amyloid A (SAA).  These same cytokines along with the 
growth factors vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), 
were also included within a high performing panel identified by our group through an 
investigation of circulating inflammatory molecules which complement the diagnostic ability of 
CA 125 105.  Other factors prominent among those identified in multimarker panel development 
include ApoAI and transthyretin (TTR), two emerging biomarkers associated with malignancy 65, 
256.   
5.2.3 Biomarker panels in the triage of women with a pelvic mass 
A collaborative group of investigators led by Robert Bast, Steven Skates and Richard Moore has 
provided the most promising results to date regarding the use of biomarker panels for the 
discrimination of benign from malignant pelvic masses.  The work of this group and several 
other notable reports are summarized in Table 5.3.  Early efforts in this diagnostic setting were 
characterized by the use of CA 125 in combination with several other glycoprotein tumor 
antigens including CA 72-4, CA 15-3, OVX-1, and LASA 142, 185, 257.  More recent reports reflect 
the emergence of HE4 as a biomarker of ovarian cancer and its effective use in this clinical 
setting.   In a series of publications, Moore et al. first established in a retrospective study that the 
combination of CA 125 and HE4 could discriminate benign from malignant masses with a SN of 
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76.5% at a SP of 95% 112.  This panel was then used to prospectively categorize patients as high 
or low risk for malignancy resulting in 93.8% correct classification of epithelial ovarian cancer 
patients 137.  Lastly, measurements of CA 125 and HE4 were incorporated into a scoring model 
termed the Risk of Ovarian Malignancy Algorithm (ROMA) which outperformed the Risk of 
Malignancy Index (RMI) yielding a SN of 94.3% at a SP of 75% 191.  Another group further 
demonstrated the utility of this combination of biomarkers in the discrimination of ovarian 
cancer from ovarian endometriotic cysts 258.   
 
Table 5.3  Multimarker panels which discriminate benign from malignant pelvic masses 
Panel Cases Controls SN SP Reference 
CA 125, MDK, AGR2 46 61 95.2 97.7 Rice et al.259 
CA 125, OVX1, LASA, CA 15-3, CA 72-4 192 237 90.6 93.2 Woolas et al. 142 
CA 125, G-CSF, IL-6, EGF, VEGF 44 37 86.5 93 Gorelik et al. 105 
CA 125, CA 72-4, CA 15-3, M-CSF 90† 228† 71 98 Zhang et al. 185 
CA 125, IL-7 187 45 69 100 Lambeck et al. 110 
ROMA* 145 312 94.3 75 Moore et al. 191 
CA 125, HE4 491† 299† 83 85 Nolen et al. 177 
CA 125, HE4 129 352 92.3 75 Moore et al.  137 
CA 125, CA 15-3, CA 72-4, LASA 182† 237† 87.5 79 Zhang et al. 257 
*Risk of ovarian malignancy algorithm; †includes independent validation set 
 
The results reported in Chapter 3 of this dissertation describe the independent 
identification of the CA 125/HE4 combination as the best possible biomarker panel for the 
discrimination of benign and malignant pelvic masses.  The current study utilized a somewhat 
larger patient cohort than that of Moore et al. 112, and also evaluated a much larger pool of 
candidate biomarkers.  A subsequent study utilizing urine as the testing matrix (Chapter 4) 
identified the same panel and suggested an optimal combination of urine HE4 and serum CA 
125.  Thus, accumulating evidence indicates a high degree of clinical utility for a biomarker-
based diagnostic tool based on this combination, with implementation possible in the near future.   
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5.3 FUTURE PERSPECTIVES 
The use of biomarkers in targeted therapies for ovarian cancer will require the concerted 
development of novel therapeutics and predictive biomarkers.  As our knowledge regarding the 
specific etiologies of the various subtypes of ovarian cancer continues to expand, so must the 
identification and development of biomarkers associated with each subtype. The tailoring of 
treatment regimens based on disease subtyping, through the aid of biomarker testing, is a likely 
first step toward personalized treatment of ovarian cancer.  The implementation of targeted 
agents earlier in the course of treatment should also facilitate the identification of predictive 
biomarkers.  In addition to such predictive markers, biomarkers of tolerability will be equally 
useful in efforts to identify combinations of targeted agents which are safe and effective.          
Several significant hurdles remain before any biomarker-based diagnostic model can be 
implemented clinically on a widespread basis.  Foremost is the need to evaluate the most 
promising panels in prospective randomized clinical trials.  Additional preclinical validation will 
be required to more fully characterize the efficacy of selected panels before this significant next 
step is warranted.  A key component of this validation process is the evaluation of such panels in 
samples obtained from prediagnostic ovarian cancer patients.  Progress towards this type of 
validation is greatly hindered by the rarity of this sample type, however several significant 
findings have been reported by a group under the direction of Nicole Urban.  In a pair of reports, 
this group first describes elevated levels of CA 125, HE4, and mesothelin in the sera of 
symptomatic ovarian cancer patients 260 and then in the sera of patients 0-3 years prior to 
diagnosis, although an optimal lead time of 1 year is noted 261.  Recently, a collaborative study 
was performed to assess pre-diagnostic performance of candidate biomarkers in the Prostate, 
Lung, Colorectal and Ovarian (PLCO) Cancer Study 262.  The study demonstrated that CA 125 
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offers robust performance in the interval 0-6 months prior to diagnosis, however the multivariate 
analysis did not yield a biomarker panel with an appreciable improvement in sensitivity over that 
of CA 125 alone for this interval.  The performance of CA 125 significantly diminished to a SN 
of 33% at 95% SP during the 6-12 months prior to diagnosis, and further decreased to 12% at 12-
18 months prior to diagnosis.  Unfortunately, none of the studied biomarkers either individually 
or in combination could offer a better performance for these pre-diagnostic intervals.   
The promising performance of urine biomarkers in the current study suggests the 
possibility that other alternative biofluids may offer similar advantages.  The saliva proteome is 
known to consist of 1166 distinct proteins including a spectrum of full length proteins, peptides, 
hormones, and enzymes 263.  Although saliva contains a relatively low overall protein 
concentration 264, modern assay methodologies displaying improved levels of sensitivity now 
permit the reliable detection of low abundance proteins.   As expected, much of the work 
regarding the use of salivary biomarkers for cancer diagnosis has focused on oral cancer 265-266, 
however several groups have extended this type of work to cancers of remote origins with 
promising results.  Gao et al. performed an analysis of salivary biomarker profiles of melanoma 
and non-small cell lung cancer using a mouse model system which not only identified several 
descriptive profiles but also characterized the origins of these factors as a combination of local 
and remote secretion 267.  Elsewhere, Streckfus et al. identified the soluble fragment of c-erbB-2 
in saliva samples taken from patients diagnosed with breast cancer but not in samples obtained 
from healthy or benign control subjects 268.  Additional work by this group, employing proteomic 
methodology, suggests that many additional breast cancer-related proteins are present in saliva 
269.  Recently, a separate group reported on the ability of panel of salivary biomarkers consisting 
of both proteins and nucleic acids to discriminate breast cancer cases from controls with a SN of 
 84 
83% at a SP of 97% 270.  The evaluation of salivary biomarkers has yet to be applied to ovarian 
cancer in a significant capacity, however several studies have examined the relationship between 
serum and salivary CA 125 with mixed results.  In two separate studies focusing on breast 271 and 
ovarian cancer 272, salivary CA 125 was found to be significantly elevated in both groups of 
cancer patients in comparison to their respective control groups, however serum and salivary 
levels of CA 125 were only correlated in the former study.  In a third study which examined a 
limited number of ovarian cancer patients, salivary CA 125 was found to provide a lower SN 
than serum CA 125, however the false-positive rate in saliva was also significantly reduced 
leading the authors to conclude that salivary CA 125 may offer improved diagnostic potential 273.  
Collectively, these findings reflect considerable promise for the expanded analysis of salivary 
biomarkers in ovarian cancer. 
The body of work contained herein outlines the vast and diverse potential for the use of 
non-invasive biomarkers of ovarian cancer.  The continued development of ovarian cancer 
biomarkers should not only permit the improved detection of the disease at a stage when curative 
treatment is far more likely, but also the improved triage and targeting of individual patients so 
that the impact of treatment can be maximized.  Synergistic coupling of biomarker development 
and advances in treatment options should greatly reduce the impact of this devastating disease.   
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